Sol-Gel Technologies Ltd. - 1684693

0001178913-24-002666.txt : 20240816 0001178913-24-002666.hdr.sgml : 20240816 20240816071539 ACCESSION NUMBER: 0001178913-24-002666 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240816 DATE AS OF CHANGE: 20240816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sol-Gel Technologies Ltd. CENTRAL INDEX KEY: 0001684693 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38367 FILM NUMBER: 241214124 BUSINESS ADDRESS: STREET 1: 7 GOLDA MEIR ST. STREET 2: WEIZMANN SCIENCE PARK CITY: NESS ZIONA STATE: L3 ZIP: 7403648 BUSINESS PHONE: 97289313433 MAIL ADDRESS: STREET 1: 7 GOLDA MEIR ST. STREET 2: WEIZMANN SCIENCE PARK CITY: NESS ZIONA STATE: L3 ZIP: 7403648 6-K 1 zk2431829.htm 6-K Sol-Gel Technologies Ltd. - 1684693 - 2024

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of August 2024

Commission File Number 001-38367

SOL-GEL TECHNOLOGIES LTD.

(Translation of registrant’s name into English)

7 Golda Meir Street

Ness Ziona 7403650, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On August 16, 2024, Sol-Gel Technologies Ltd. (the “Company”) issued a press release announcing the Company's financial results for the quarter ended June 30, 2024. In addition, the Company is submitting with this Form 6-K its unaudited condensed consolidated financial statements as of June 30, 2024 and for the three and six months then ended.

Attached hereto are the following exhibits:

Exhibit 99.1

Press release dated August 16, 2024

Exhibit 99.2

Unaudited condensed consolidated financial statements as of June 30, 2024 and for the three and six months then ended.

Exhibit 99.1 (other than the two paragraphs immediately preceding the heading “Q2 2024 and Recent Corporate Developments”) and 99.2 are hereby incorporated by reference into the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915 and 333-270477) and its Registration Statement on Form F-3 (Registration No 333-264190).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SOL-GEL TECHNOLOGIES LTD.

Date: August 16, 2024	By:	/s/ Eyal Ben-Or
		Eyal Ben-Or
		Chief Financial Officer

EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1

Exhibit 99.1

Sol-Gel Reports Second Quarter 2024 Financial

Results and Provides Corporate Updates

•

Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026

•

Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026

•

SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing

•

Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve® Cream (roflumilast cream 0.3%)

•

Following management realignment, Mr. Mori Arkin, the Company’s executive chairman and controlling shareholder to be appointed as Company’s interim CEO as of January 1, 2025, subject to shareholders approval

•

Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories

NESS ZIONA, Israel, August 16 2024 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.

Q2 2024 and Recent Corporate Developments

•

On August 15, 2024, Sol-Gel signed a new agreement with Padagis, which replaces the parties’ prior collaborative agreement for the development and commercialization of a drug product generic to Zoryve® Cream (roflumilast cream 0.3%). Under this new agreement, Sol-Gel is to unconditionally receive quarterly payments which will be paid over 24 months and low single digit royalties from gross profits from sales of roflumilast cream for a period of five years, in lieu of its 50% share in future gross profits from such sales. In addition, Sol-Gel will cease paying any outstanding and future costs related to this prior collaborative agreement. The amount to be received by Padagis together with the elimination of future expected expenses related to this asset is expected to enhance our cash position by approximately $6 million. Recognizing that TWYNEO and EPSOLAY have a significant commercial potential also outside the U.S., during July 2024, Sol-Gel has successfully signed six initial license agreements with key partners covering most European countries and South Africa. Sol-Gel expects to sign additional agreements covering the majority of Latin American countries, Australia, New Zealand, South Korea, Spain, Italy and Portugal. These already signed agreements together with agreements we anticipate to sign in the future, are expected to provide upfront and regulatory milestone payments of up to $3.7 million, which we expect to utilize on adapting TWYNEO and EPSOLAY to the regulatory requirements of these new territories. Based on the forecasts received from Sol-Gel’s current and potential partners, Sol-Gel expects that TWYNEO and EPSOLAY will launch in the majority of these new territories in 2027 and 2026 respectively, and following launch these transactions are anticipated to provide Sol-Gel with an annual royalty revenue stream starting with approximately $1 million to $2 million in 2026 and growing gradually to approximately up to $10 million for the year 2030 and further.

•

The Phase 3 study in Sol-Gel’s key asset SGT-610 in approximately 140 subjects (with 100 subjects required to complete the Study), at about 42 experienced clinical centers is ongoing. To date, Sol-Gel has signed agreements with 39 centers in multiple countries, including the U.S., Germany, Italy, France, and the UK, and approximately 29 of these enters have been activated. Top line results are anticipated in Q2 2026. SGT-610 is a topically applied patidegib, a hedgehog signaling pathway blocker 2% gel If approved, SGT-610 is expected to be the first approved product for the prevention of new BCC lesions in Gorlin syndrome patients and is targeting a market exceeding $300 million annually.

•

Sol-Gel’s proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease is ongoing. Darier disease is a significant unmet medical need, with a market potential estimated between $200 to $300 million. If we successfully complete this proof-of-concept study and the required pre-clinical studies, we anticipate filing for a Phase 2 IND in Q2 2025. SGT-210 is currently being used in a compassionate use treatment of a pediatric patient suffering from a rare disease, and given the preliminary highly encouraging response, we are cautiously optimistic about the potential for success in other viable keratoderma indications, recognizing that further research and clinical studies are necessary to validate any broader applications of our therapy.

•

Subject to shareholders approval, Mr. Arkin, the Company’s executive chairman and controlling shareholder, who has several decades of experience in leading positions in the pharmaceutical industry and in the dermatological space in particular, will assume the role of interim CEO as of January 1, 2025. During his tenure as interim CEO, Mr. Arkin plans to transition away from the majority of his other business activities in order to dedicate himself to his new full time position as interim CEO of the Company. Mr. Arkin will not be entitled to any compensation for assuming this position. On July 15, 2024, Sol-Gel announced management realignment whereby pending shareholder approval our CEO Dr. Alon Seri-Levy will step down as CEO and Board member, effective December 31, 2024, and will then continue to serve the Company as a consultant to our new CEO and management team for at least one year.

•

Effective July 12, 2024, Mr. Eyal Ben-Or, the Company's previous Director of Finance, assumed the role of Chief Financial Officer (CFO). Prior to his employment in Sol-Gel Mr. Ben-Or worked at Mobileye and KPMG Israel. Mr. Ben-Or, is a certified public accountant, holds an MBA and a BA in accounting from the College of Management in Israel. Mr. Ben-Or replaces the Company’s previous CFO, Mr. Gilad Mamlok, who will facilitate the transition through December 31, 2024.

Mr. Mori Arkin, Executive Chairman of Sol-Gel, stated: "We are encouraged by Sol-Gel’s financial results for the second quarter of 2024 and our ability to extend our cash runway into the first quarter of 2026. We will continue to explore opportunities for non-dilutive funding to potentially further extend our runway through topline results. In our pipeline, we continue to conduct the pivotal Phase 3 clinical trial of SGT-610 for preventing new basal cell carcinomas in Gorlin Syndrome patients, targeting a market exceeding $300 million, with top line results anticipated in the second quarter of 2026 along with our proof-of-concept study for SGT-210 (topical erlotinib) in Darier disease patients targeting a market of between $200 to $300 million. These two rare disease projects reflect the huge growth potential of a company of our size. The Sol-Gel management team and I are committed to spare no effort to realize this potential"

Financial Results for the Second Quarter 2024

Total revenue in the second quarter was $5.4 million, which primarily consisted of a one-time licensing revenue from Beimei, Galderma and Searchlight, compared to $0.6 million revenues for the same period in 2023.

Research and development expenses were $2.4 million compared to $5.3 million for the same period in 2023. The decrease of $2.9 million was primarily attributed to a decrease of $0.7 million in manufacturing expenses related to TWYNEO, a decrease of $0.7 million in clinical development expenses related to a generic product candidate, a decrease of $0.5 million in payroll expenses due to the adoption of cost saving measures initiated during the third quarter of 2023, a decrease of $0.5 related to R&D expenses, a decrease of $0.3 million in clinical trial expenses related to SGT-610 and a decrease of $0.2 in clinical expenses related to SGT-210.

General and administrative expenses were $1.4 million compared to $1.8 million for the same period in 2023. The decrease of $0.4 million was mainly attributed to a decrease in professional expenses.

Sol-Gel reported a net income of $1.9 million for the second quarter of 2024 and earnings of $0.07 per basic and diluted share, compared to a net loss of $6.0 million and a loss of $0.22 per basic and diluted share for the same period in 2023.

As of June 30, 2024, Sol-Gel had $15.6 million in cash, cash equivalents, and deposits and $14.9 million in marketable securities for a total balance of $30.5 million. The Company expects its cash resources to fund cash requirements into the first quarter of 2026.

About TWYNEO and EPSOLAY

TWYNEO is a topical cream containing a fixed-dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, cream for the treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. TWYNEO is the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin. Tretinoin and benzoyl peroxide are widely prescribed separately for acne vulgaris; however, benzoyl peroxide causes degradation of the tretinoin molecule, thereby potentially reducing its effectiveness if used at the same time or combined in the same formulation. TWYNEO uses silica (silicon dioxide) core shell structures to separately micro-encapsulate tretinoin crystals and benzoyl peroxide crystals enabling inclusion of the two active ingredients in the cream.

EPSOLAY is a topical cream containing benzoyl peroxide (BPO), 5%, for the treatment of bumps and blemishes (inflammatory lesions) of rosacea in adults. EPSOLAY utilizes a proprietary, patented technology to encapsulate BPO within silica-based microcapsules to create a barrier between the medication and the skin. The silica-based shell is designed to slowly release BPO over time to provide a tolerable and effective treatment.

About Gorlin Syndrome and SGT-610

SGT-610, a hedgehog signaling pathway blocker, has the potential to be the first ever treatment for prevention of BCCs in Gorlin syndrome patients, if approved. Gorlin syndrome, an autosomal dominant genetic disorder affecting approximately 1 in 27,000-31,000 people in the U.S., is mostly caused by inheritance of one defective copy of the tumor suppressor patched homolog 1 (PTCH1) gene. Normally, the PTCH1 gene blocks the smoothened, frizzle class receptor (SMO) gene, turning off the hedgehog signaling pathway when it is not needed. Mutations in the PTCH1 gene may cause a loss of PTCH1 function, release of SMO, and may allow BCC tumor cells to divide uncontrollably. Patidegib, the active substance in SGT-610, is designed to block the SMO signal, thus, allowing cells to function normally and reducing the production of new tumors.

About Darier Disease and SGT-210

SGT-210 is a topical erlotinib drug candidate that is formulated for the treatment of Darier Disease and other hyperkeratosis-related indications. Erlotinib is a tyrosine kinase receptor inhibitor that acts on the epidermal growth factor receptor, a protein present on cell surfaces that plays a key role in promoting cell growth and division. Darier Disease is a rare, genetic keratinization disorder which is classically characterized scaly crusted papules in a seborrheic distribution and in skin folds.

About Sol-Gel Technologies

Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products to treat skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.

The Company’s pipeline also includes Phase 3 clinical trial of Orphan and breakthrough drug candidate SGT-610, which is a new topical hedgehog inhibitor being developed to prevent the new basal cell carcinoma lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors as well as topical drug candidate SGT-210 under investigation for the treatment of rare hyper keratinization disorders.

For additional information, please visit our new website: www.sol-gel.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to the amounts to be received under our current and future licensing agreements and our agreement with Padagis with respect to the generic drug product to Zoryve^® Cream (roflumilast cream, 0.3%), the out-licensing Twyneo and Epsolay in additional territories, our expected cash runway, the expected royalties amounts to be received from Galderma, the potential of Sol-Gel’s assets including Twyneo, Epsolay, SGT-610, and SGT-210, the timeline for advancing SGT-610 and SGT-210, and the size of SGT-610’s market. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management’s current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, our ability to enter into further collaborations, lower than anticipated annual revenue income from new collaborations, a delay in the timing of our clinical trials, the success of our clinical trials, and an increase in our anticipated costs and expenses, as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaborators’ ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaborators’ ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators’ ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, China, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and, (xvii) the current war between Israel and Hamas and any deterioration of the war in Israel into a broader regional conflict involving Israel with other parties. These factors and other important factors discussed in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 13, 2024, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this press release.

Sol-Gel Contact:

Eyal Ben-Or

Chief Financial Officer

info@sol-gel.com

+972-8-9313429

Source: Sol-Gel Technologies Ltd.

SOL-GEL TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

	December 31,			June 30,
	2023			2024
A s s e t s
CURRENT ASSETS:
Cash and cash equivalents	$	7,513		$	11,549
Bank deposits		10,012			4,012
Marketable securities		20,471			14,912
Accounts receivables		377			6,059
Prepaid expenses and other current assets		2,794			1,750
TOTAL CURRENT ASSETS		41,167			38,282

NON-CURRENT ASSETS:
Restricted long-term deposits and cash equivalents		1,284			1,273
Property and equipment, net		434			305
Operating lease right-of-use assets		1,721			1,507
Other long-term assets		55			34
Funds in respect of employee rights upon retirement		626			604
TOTAL NON-CURRENT ASSETS		4,120			3,723
TOTAL ASSETS	$	45,287		$	42,005
Liabilities and shareholders' equity
CURRENT LIABILITIES:
Accounts payable	$	154		$	679
Other accounts payable		3,921			4,147
Current maturities of operating leases		447			376
TOTAL CURRENT LIABILITIES		4,522			5,202

LONG-TERM LIABILITIES
Operating leases liabilities		1,206			1,018
Liability for employee rights upon retirement		915			883
TOTAL LONG-TERM LIABILITIES		2,121			1,901
TOTAL LIABILITIES		6,643			7,103

SHAREHOLDERS' EQUITY:
Ordinary Shares, NIS 0.1 par value – authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of December 31, 2023 and June 30, 2024.		774			774
Additional paid-in capital		258,173			258,799
Accumulated deficit		(220,303	)		(224,671	)
TOTAL SHAREHOLDERS' EQUITY		38,644			34,902
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	45,287		$	42,005

SOL-GEL TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

	Six months ended June 30						Three months ended June 30
	2023			2024			2023			2024
REVENUE	$	894		$	5,899		$	594		$	5,433
RESEARCH AND DEVELOPMENT EXPENSES		14,698			7,783			5,312			2,438
GENERAL AND ADMINISTRATIVE EXPENSES		3,786			3,203			1,809			1,371
OPERATING INCOME (LOSS)	$	(17,590	)	$	(5,087	)	$	(6,527	)	$	1,624
FINANCIAL INCOME, net		899			719			557			352
NET INCOME (LOSS) FOR THE PERIOD	$	(16,691	)	$	(4,368	)	$	(5,970	)	$	1,976
BASIC AND DILUTED EARNINGS (LOSS) PER ORDINARY SHARE	$	(0.63	)	$	(0.16	)	$	(0.22	)	$	0.07
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE		26,306,484			27,857,620			27,660,326			27,857,620

EX-99.2 3 exhibit_99-2.htm EXHIBIT 99.2 Sol-Gel Technologies Ltd. - 1684693 - 2024

Exhibit 99.2

SOL-GEL TECHNOLOGIES LTD.

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2024

SOL-GEL TECHNOLOGIES LTD.

UNAUDITED CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2024

TABLE OF CONTENTS

	Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
Balance Sheets	F - 2
Statements of Operations	F - 3
Statements of Changes in Shareholders' Equity	F - 4 - F - 5
Statements of Cash Flows	F - 6
Notes to the Financial Statements	F - 7 - F - 13

_______________________________

_____________________________________________

_______________________________

The amounts are stated in U.S. dollars in thousands, except share and per share data

SOL-GEL TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

	December 31,			June 30,
	2023			2024
A s s e t s
CURRENT ASSETS:
Cash and cash equivalents	$	7,513		$	11,549
Bank deposits		10,012			4,012
Marketable securities		20,471			14,912
Accounts receivables		377			6,059
Prepaid expenses and other current assets		2,794			1,750
TOTAL CURRENT ASSETS		41,167			38,282

NON-CURRENT ASSETS:
Restricted long-term deposits and cash equivalents		1,284			1,273
Property and equipment, net		434			305
Operating lease right-of-use assets		1,721			1,507
Other long-term assets		55			34
Funds in respect of employee rights upon retirement		626			604
TOTAL NON-CURRENT ASSETS		4,120			3,723
TOTAL ASSETS	$	45,287		$	42,005
Liabilities and shareholders' equity
CURRENT LIABILITIES:
Accounts payable	$	154		$	679
Other accounts payable		3,921			4,147
Current maturities of operating leases		447			376
TOTAL CURRENT LIABILITIES		4,522			5,202

LONG-TERM LIABILITIES
Operating leases liabilities		1,206			1,018
Liability for employee rights upon retirement		915			883
TOTAL LONG-TERM LIABILITIES		2,121			1,901
TOTAL LIABILITIES		6,643			7,103

SHAREHOLDERS' EQUITY:
Ordinary Shares, NIS 0.1 par value – authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of December 31, 2023 and June 30, 2024.		774			774
Additional paid-in capital		258,173			258,799
Accumulated deficit		(220,303	)		(224,671	)
TOTAL SHAREHOLDERS' EQUITY		38,644			34,902
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	45,287		$	42,005

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F - 2

SOL-GEL TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

	Six months ended June 30						Three months ended June 30
	2023			2024			2023			2024
REVENUE	$	894		$	5,899		$	594		$	5,433
RESEARCH AND DEVELOPMENT EXPENSES		14,698			7,783			5,312			2,438
GENERAL AND ADMINISTRATIVE EXPENSES		3,786			3,203			1,809			1,371
OPERATING INCOME (LOSS)	$	(17,590	)	$	(5,087	)	$	(6,527	)	$	1,624
FINANCIAL INCOME, net		899			719			557			352
NET INCOME (LOSS) FOR THE PERIOD	$	(16,691	)	$	(4,368	)	$	(5,970	)	$	1,976
BASIC AND DILUTED EARNINGS (LOSS) PER ORDINARY SHARE	$	(0.63	)	$	(0.16	)	$	(0.22	)	$	0.07
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE		26,306,484			27,857,620			27,660,326			27,857,620

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F - 3

SOL-GEL TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

	Ordinary shares				Additional paid-in capital		Accumulated deficit			Total
	Number of shares		Amounts		Amounts
BALANCE AS OF JANUARY 1, 2023		23,129,469		638		234,640		(193,065	)		42,213
CHANGES DURING THE SIX MONTHS ENDED JUNE 30, 2023:
Loss for the period								(16,691	)		(16,691	)
Issuance of shares and warrants through public offering, net of issuance costs		2,560,000		74		11,468					11,542
Issuance of shares and warrants through private placement from the controlling shareholder		2,000,000		56		9,944					10,000
Exercise of options		116,485		3		177					180
Share-based compensation						1,052					1,052
BALANCE AT JUNE 30, 2023		27,805,954		771		257,281		(209,756	)		48,296

BALANCE AS OF JANUARY 1, 2024		27,857,620		774		258,173		(220,303	)		38,644
CHANGES DURING THE SIX MONTHS ENDED JUNE 30, 2024:
Loss for the period		-		-				(4,368	)		(4,368	)
Share-based compensation		-		-		626					626
BALANCE AT JUNE 30, 2024		27,857,620		774		258,799		(224,671	)		34,902

F - 4

SOL-GEL TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

	Ordinary shares				Additional paid-in capital		Accumulated deficit			Total
	Number of shares		Amounts		Amounts
BALANCE AS OF APRIL 1, 2023		25,702,237		712		246,678		(203,786	)		43,604
CHANGES DURING THE THREE MONTHS ENDED JUNE 30, 2023:
Loss for the period								(5,970	)		(5,970	)
Issuance of shares and warrants through private placement from the controlling shareholder		2,000,000		56		9,944					10,000
Exercise of options		103,717		3		161					164
Share-based compensation						498					498
BALANCE AT JUNE 30, 2023		27,805,954		771		257,281		(209,756	)		48,296

BALANCE AS OF APRIL 1, 2024		27,857,620		774		258,524		(226,647	)		32,651
CHANGES DURING THE THREE MONTHS ENDED JUNE 30, 2024:
Income for the period		-		-				1,976			1,976
Share-based compensation		-		-		275					275
BALANCE AT JUNE 30, 2024		27,857,620		774		258,799		(224,671	)		34,902

* less than $1 thousand.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

F - 5

SOL-GEL TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

	Six months ended June 30
	2023			2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Loss for the period	$	(16,691	)	$	(4,368	)
Adjustments required to reconcile loss to net cash used in operating activities:
Depreciation		185			125
Changes in accrued liability for employee rights upon retirement, net		9			(10	)
Share-based compensation expenses		1,052			626
Financial expenses (income), net		(1	)		(2	)
Net changes in operating leases		(36	)		(45	)
Changes in fair value of marketable securities		(66	)		(87	)
Changes in operating asset and liabilities:
Receivables from collaborative and licensing arrangements		5,653			-
Accounts receivables		-			(5,682	)
Prepaid expenses and other current assets		(1,063	)		1,065
Accounts payable, accrued expenses and other		2,623			751
Net cash used in operating activities		(8,335	)		(7,627	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(94	)		-
Proceeds from sale of property and equipment		-			4
Investment in marketable securities		(17,114	)		-
Proceeds from sales and maturity of marketable securities		7,995			5,646
Short-term deposits		(1,000	)		6,000
Long-term deposits		12			821
Net cash provided by (used in) investing activities		(10,201	)		12,471
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of options		180			-
Proceeds from issuance of shares and warrants through placement from the controlling shareholder		10,000			-
Proceeds from issuance of shares and warrants through public offering, net of issuance costs		11,542			-
Net cash provided by financing activities		21,722			-
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS		1			2
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS		3,187			4,846
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD		13,598			7,863
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	$	16,785		$	12,709
Cash and Cash equivalents		15,618			11,549
Restricted cash		1,167			1,160
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS		16,785			12,709
SUPPLEMENTARY DISCLOSURE OF NON-CASH ACTIVITIES:
Recognition of new operating lease ROU and liabilities	$	190			-
SUPPLEMENTARY INFORMATION:
Interest received	$	590		$	1,121

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F - 6

SOL-GEL TECHNOLOGIES LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. dollars in thousands, except share and per share data)

(Unaudited)

NOTE 1 - NATURE OF OPERATIONS

Sol-Gel Technologies Ltd. (collectively with its U.S. subsidiary, the Company) is an Israeli Company incorporated in 1997.

The Company is an innovative dermatology company with a successful track record of two NDA approvals and advanced orphan drugs pipeline. The Company has two approved drugs: (i) Twyneo®, which was developed for the treatment of acne vulgaris and received marketing authorization by the U.S. Food and Durg Administration (the "FDA") on July 27, 2021 and (ii) Epsolay®, a treatment for subtype II rosacea that received marketing authorization by the FDA on April 25, 2022. In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of Twyneo® and Epsolay® in the United States, see Note 6a. On April 14, 2022, the Company announced that Twyneo® is available for purchase by consumers who obtain a prescription from their physician. On June 2, 2022, the Company announced that Epsolay® is available for purchase by consumers who obtain a prescription from their physician. In addition to the novel products, the Company’s products included the approved generic products Acyclovir, Ivermectin and other generic product candidates. In November 2021, the Company entered into an agreement with Padagis, to sell its rights in relation to ten generic collaborative agreements between the parties, including the agreements for the two aforementioned approved generic drug products. Under the new agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, see note 5c.

On January 27, 2023 the Company entered into an asset purchase agreement ("APA") with PellePharm, Inc. (hereafter-“PellePharm”), pursuant to which the Company agreed to purchase all of the assets related to the topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome (such compound designated as investigational compound SGT-610). On January 30, 2023, upon closing of the transaction, the Company paid an upfront payment (hereafter- "upfront payment") of $4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date. In addition, the Company will be required to pay total development and NDA acceptance milestones of up to $6 million, and up to $64 million in commercial milestones which amount increases to $89 million when sales exceed $500 million as well as single digit royalties which increase to double digit royalties when sales exceed $500 million. During March 2024 the first developement milestone event has completed and the Company recorded an amount of $500 as clinical expenses.

The upfront payment and the additional development milestone payments under the APA represent payments for research and development in-process ("IPR&D") acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use. Accordingly, such payments were expensed as incurred and recognized as research and development expenses.

On May 15, 2024, the Company and Shenzhen Beimei Pharmaceutical Co. Ltd. ("Beimei"), entered into an asset purchase agreement, For further details, see Note 6c.

The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regards to marketing, regulatory affairs and business development relating to its products and technology in the U.S.

In October 2023, Hamas terrorists infiltrated Israel’s southern border and launched a series of attacks against Israel. Following these attacks, Israel’s security cabinet declared war against Hamas and initiated a military campaign. As of the issuance date of this report, there was no material impact on the Company's ongoing operations in Israel. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employee

F - 7

SOL-GEL TECHNOLOGIES LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. dollars in thousands, except share and per share data)

(Unaudited)

NOTE 1 - NATURE OF OPERATIONS (continued):

Risk and Uncertainties

Since incorporation through June 30, 2024, the Company has an accumulated deficit of $224,671 and its activities have been funded mainly by its shareholders, collaboration revenues and license agreements, see also Notes 5 and 6. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations.

Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of June 30, 2024 will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.

The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.

Earnings (Loss) per share

Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.

The calculation of diluted earnings per share, does not include 6,501,769 options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.

The calculation of diluted loss per share does not include 6,993,858 options and warrants for the six months ended June 30, 2024 and 5,961,999 and 7,120,463 options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.

F - 8

SOL-GEL TECHNOLOGIES LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. dollars in thousands, except share and per share data)

(Unaudited)

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (continued):

Recently issued accounting pronouncements, not yet adopted

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.

NOTE 3 - MARKETABLE SECURITIES:

The following table sets forth the Company’s marketable securities for the indicated periods:

	December 31,		June 30,
	2023		2024
Level 2 securities:
U.S government and agency bonds		2,583		1,612
Other foreign government bonds		1,946		1,974
Corporate bonds*		15,942		11,326
Total		20,471		14,912

* Investments in Corporate bonds rated A or higher.

The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis.

The Company’s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.

The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the indicated periods:

	Marketable securities
	For the year ended			For the six months
	December 31, 2023			ended June 30, 2024

Balance at beginning of the period	$	8,678		$	20,471
Additions		23,164			-
Sale or maturity		(11,807	)		(5,646	)
Changes in fair value during the period		436			87
Balance at end of the period	$	20,471		$	14,912

F - 9

SOL-GEL TECHNOLOGIES LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. dollars in thousands, except share and per share data)

(Unaudited)

NOTE 3 - MARKETABLE SECURITIES (continued):

As of June 30, 2024, the Company’s debt securities had the following maturity dates:

	Market value
	June 30,
	2024
Due within one year	$	14,912

The fair value of bank deposits approximates their carrying value, since they bear interest at rates close to the prevailing market rates. In addition, due to the short-term nature and/or low-risk nature of the Company's cash and cash equivalents, restricted cash equivalents, accounts receivable, accounts payable and other payables , their carrying amounts approximates their fair value

NOTE 4 - REVENUE:

The following table sets forth the Company’s revenues for the indicated periods:

	Six months ended June 30				Three months ended June 30
	2023		2024		2023		2024
Royalties revenue	$	514	$	1,056	$	214	$	612
Sale of IP and license revenue		380		4,800		380		4,800
Support services		-		43		-		21
Total revenue	$	894	$	5,899	$	594	$	5,433

NOTE 5 - COLLABORATION AGREEMENTS:

In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales, royalties are not material.

In 2016 through 2020, the Company entered into several collaboration agreements mainly with one third party (the "Partner") for the development, manufacturing and commercialization of several product candidates (including an agreement assumed by the Company in August 2018, following the transfer of an in-process research and development product candidate from a related party).

Under the agreements, the Partner is obligated to conduct regulatory, scientific, clinical and technical activities necessary to develop the products and prepare and file an abbreviated new drug application ("ANDA"), with the FDA and gain regulatory approval. The Company participates in the development of the product candidates, including participation in joint steering committees and is obligated for sourcing the active pharmaceutical ingredient (API) during the development phase.

Upon FDA approval, the Partner has exclusive rights and is required to use diligent efforts to commercialize these products in territories defined under the agreements, including all required sales, marketing and distributing activities associated with the agreements. The Company is entitled to a share of the Partner's gross profits related to the sale of the products, as such term is defined in each of the agreements.

F - 10

SOL-GEL TECHNOLOGIES LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. dollars in thousands, except share and per share data)

(Unaudited)

NOTE 5 - COLLABORATION AGREEMENTS (continued):

These Agreements are considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company recognizes collaboration revenues when the related sales occur.

In November 2021, the Company entered into a new agreement ("New Agreement") with the Partner, to sell its rights to the Partner in relation to ten generic collaborative agreements between the parties in consideration of $21,500 which was paid over 24 months. Under the New Agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, and is no longer entitled to receive its share in profit as detailed above.

In addition, the Company ceased paying any outstanding and future operational costs related to these collaborative agreements.

In August 15, 2024 the Company entered into a Termination Agreement with the Partner, For further details, see note 9.

NOTE 6 - AGREEMENTS:

In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of two of the Company's most advanced investigational drug products (Twyneo® and Epsolay®) in the United States. The Company was entitled to amounts of up to $7.5 million per product in upfront payments and regulatory approval milestone payments assuming 2021 approval of each respective product. The Company is also eligible to receive tiered double-digit royalties ranging from mid-teen to high-teen percentage of net sales as well as up to $9 million in sales milestone payments.

According to the agreement, the Company has an option to regain commercialization rights five years following first commercialization.

On April 14, 2022, the Company announced that Twyneo® is available for purchase by consumers who obtain a prescription from their physician, See note 1. On June 2, 2022, the Company announced that Epsolay® is available for purchase by consumers who obtain a prescription from their physician, See also note 1. The Company recognized $723 and $466 during the six-month periods ended June 30, 2024 and 2023, respectively, as royalty revenue in respect of the license agreement for both products.

On June 6, 2023, the Company and Searchlight Pharma Inc. (“Searchlight”), a private Canadian specialty pharmaceutical company, signed on an exclusive license agreements for Twyneo® and Epsolay® for the Canadian market, over a fifteen-year term that is renewable for subsequent five-year periods. Searchlight will be responsible for obtaining and maintaining any regulatory approvals required to market and sell the drugs in Canada, with support from the Company.

Under the agreement, the Company will receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined. In addition, the Company will be entitled to royalty percentages of all Canadian net sales ranging from low-double-digits to high teens.

F - 11

SOL-GEL TECHNOLOGIES LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. dollars in thousands, except share and per share data)

(Unaudited)

NOTE 6 - AGREEMENTS (continued):

In June 2023, the Company received $500 as an upfront payment in connection with the license agreement and related support provided to Searchlight for obtaining the regulatory approval in the Canadian market. The Company is also required to support Searchlight during such period if needed based on agreed upon rates. The Company has identified two performance obligations in the license agreement as follows: (i) the license to market the products in Canada; and (ii) continuing support during the regulatory approval process.

For the six-month period ended June 30, 2024, the Company recognized a total amount of $42 for continuing support. The remaining outstanding contract liability in respect of the support services, is, as of June 30, 2024 $78 .

On May 15, 2024, the Company and Beimei, a private Chinese company, signed an agreement for the purchase and license by Beimei of certain rights in the intellectual property ("IP") related to Twyneo, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.

Under the terms of the agreement, Beimei will purchase and license from the Company the IP in these territories. The Company is also required to support Beimei to a certain extent during the period until obtaining regulatory approval. The Company may provide further support services to Beimei, if needed, based on agreed upon rates. In return, Sol-Gel is to receive payments of up to $10 million (including amounts contingent on achieving certain milestones) and up to $5 million as royalty payments on net sales.

The Company has identified multiple performance obligations in the agreement. Revenue from sale and license of IP is recognized at a point in time, upon transfer of control over the license and the IP to Beimei. Support services are recognized over time as the services are performed.

For the six-month period ended June 30, 2024, the Company recognized revenue for a total amount of $4.8 million. This amount does not include variable consideration that was determined to be constrained (not probable that would not result in a significant reversal). In addition, the Company recorded $200 as a contract liability in respect of the support services.

In July 2024, the Company received $2 million as the first payment in connection with the agreement.

F - 12

SOL-GEL TECHNOLOGIES LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. dollars in thousands, except share and per share data)

(Unaudited)

NOTE 7 - SHARE BASED COMPENSATION:

During the six months ended June 30, 2024, the Company granted 300,000 options to Directors as follows:

In January 2024, the board of directors approved and recommended the Company's shareholders to approve a grant of 300,000 options to the Company's Directors to purchase ordinary shares at an exercise price of $1.2 per share. The Company's shareholders approved the grant in February 28, 2024.

The options vest over a period of 3 years; one third of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over the following two years. The options expire on the tenth anniversary of their grant date.

The fair value of options granted in 2024 was $207. The underlying data used for computing the fair value of the options are as follows:

	2024
Value of one ordinary share	$	1.2
Dividend yield		0	%
Expected volatility		72	%
Risk-free interest rate		4.8	%
Expected term	4 years

NOTE 8 - RELATED PARTIES:

Related parties include the controlling shareholder and companies under his control, the board of directors and the executive officers of the Company.

As to options granted to directors and executive officers, see note 7.

NOTE 9 – SUBSEQUENT EVENT

In August 15, 2024, the Company entered into a Termination Agreement ("the Agreement") with the Partner. The purpose of the Agreement is to terminate the Development, Manufacturing and Commercialization Agreement dated June 28, 2020, and to sell its rights to the Partner in relation to Roflumilast cream and Roflumilast foam. As consideration for the Agreement between the parties, the Partner will pay to the Company $4,250, which will paid in quarterly installments during 24 months. In addition, in the end of each quarter for five years as of the Launch Date (the date of first commercial sale of the Product in the Territory by the Partner or its Affiliates pursuant to the ANDA), the Partner shall pay Sol-Gel 2% royalties of the Partner’s Gross Profits for that Product.

F - 13

EX-101.SCH 4 slgl-20240630.xsd XBRL SCHEMA FILE 0001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) link:presentationLink link:definitionLink link:calculationLink 0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 0007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 0009 - Disclosure - MARKETABLE SECURITIES link:presentationLink link:definitionLink link:calculationLink 0010 - Disclosure - REVENUE link:presentationLink link:definitionLink link:calculationLink 0011 - Disclosure - COLLABORATION AGREEMENTS link:presentationLink link:definitionLink link:calculationLink 0012 - Disclosure - AGREEMENTS link:presentationLink link:definitionLink link:calculationLink 0013 - Disclosure - SHARE BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 0014 - Disclosure - RELATED PARTIES link:presentationLink link:definitionLink link:calculationLink 0015 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:definitionLink link:calculationLink 0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 0017 - Disclosure - MARKETABLE SECURITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 0018 - Disclosure - REVENUE (Tables) link:presentationLink link:definitionLink link:calculationLink 0019 - Disclosure - SHARE BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 0020 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0022 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details) link:presentationLink link:definitionLink link:calculationLink 0023 - Disclosure - MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details) link:presentationLink link:definitionLink link:calculationLink 0024 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details) link:presentationLink link:definitionLink link:calculationLink 0025 - Disclosure - REVENUE (Details) link:presentationLink link:definitionLink link:calculationLink 0026 - Disclosure - COLLABORATION AGREEMENTS (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0027 - Disclosure - AGREEMENTS (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0028 - Disclosure - SHARE BASED COMPENSATION (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0029 - Disclosure - SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details) link:presentationLink link:definitionLink link:calculationLink 0030 - Disclosure - SUBSEQUENT EVENT (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 slgl-20240630_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 slgl-20240630_def.xml XBRL DEFINITION FILE EX-101.LAB 7 slgl-20240630_lab.xml XBRL LABEL FILE EX-101.PRE 8 slgl-20240630_pre.xml XBRL PRESENTATION FILE GRAPHIC 9 image0.jpg GRAPHIC begin 644 image0.jpg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image1.jpg GRAPHIC begin 644 image1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Document and Entity Information
6 Months Ended

Jun. 30, 2024

Cover [Abstract]

Entity Central Index Key 0001684693

Current Fiscal Year End Date --12-31

Document Fiscal Year Focus 2024

Document Fiscal Period Focus Q2

Amendment Flag false

Document Type 6-K

Document Period End Date Jun. 30, 2024

Entity Registrant Name SOL-GEL TECHNOLOGIES LTD.

Entity Address, Address Line One 7 Golda Meir Street

Entity Address, City or Town Ness Ziona

Entity Address, Postal Zip Code 7403650

Entity Address, Country IL

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details

Name: dei_EntityAddressCountry

Namespace Prefix: dei_

Data Type: dei:countryCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands

Jun. 30, 2024

Dec. 31, 2023

CURRENT ASSETS:

Cash and cash equivalents $ 11,549 $ 7,513

Bank deposits 4,012 10,012

Marketable securities 14,912 20,471

Accounts receivables 6,059 377

Prepaid expenses and other current assets 1,750 2,794

TOTAL CURRENT ASSETS 38,282 41,167

NON-CURRENT ASSETS:

Restricted long-term deposits and cash equivalents 1,273 1,284

Property and equipment, net 305 434

Operating lease right-of-use assets 1,507 1,721

Other long-term assets 34 55

Funds in respect of employee rights upon retirement 604 626

TOTAL NON-CURRENT ASSETS 3,723 4,120

TOTAL ASSETS 42,005 45,287

CURRENT LIABILITIES:

Accounts payable 679 154

Other accounts payable 4,147 3,921

Current maturities of operating leases 376 447

TOTAL CURRENT LIABILITIES 5,202 4,522

LONG-TERM LIABILITIES

Operating leases liabilities 1,018 1,206

Liability for employee rights upon retirement 883 915

TOTAL LONG-TERM LIABILITIES 1,901 2,121

TOTAL LIABILITIES 7,103 6,643

SHAREHOLDERS' EQUITY:

Ordinary Shares, NIS 0.1 par value – authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of December 31, 2023 and June 30, 2024. 774 774

Additional paid-in capital 258,799 258,173

Accumulated deficit (224,671) (220,303)

TOTAL SHAREHOLDERS' EQUITY 34,902 38,644

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 42,005 $ 45,287

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details

Name: us-gaap_AccountsReceivableNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset recognized for present right to economic benefit.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset recognized for present right to economic benefit, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1
+ Details

Name: us-gaap_DefinedBenefitPlanBenefitObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1
+ Details

Name: us-gaap_DefinedBenefitPlanFairValueOfPlanAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_DepositsAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(14))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in marketable security, classified as current.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 360
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478451/942-360-50-1
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 210
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477220/954-210-45-4

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478600/954-210-50-2
+ Details

Name: us-gaap_RestrictedCashAndInvestmentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated undistributed earnings (deficit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - ₪ / shares

Jun. 30, 2024

Dec. 31, 2023

Statement of Financial Position [Abstract]

Ordinary shares, par value ₪ 0.1 ₪ 0.1

Ordinary shares, shares authorized 50,000,000 50,000,000

Ordinary shares, shares issued 27,857,620 27,857,620

Ordinary shares, shares outstanding 27,857,620 27,857,620

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

REVENUE $ 5,433 $ 594 $ 5,899 $ 894

RESEARCH AND DEVELOPMENT EXPENSES 2,438 5,312 7,783 14,698

GENERAL AND ADMINISTRATIVE EXPENSES 1,371 1,809 3,203 3,786

OPERATING INCOME (LOSS) 1,624 (6,527) (5,087) (17,590)

FINANCIAL INCOME, net 352 557 719 899

NET INCOME (LOSS) FOR THE PERIOD $ 1,976 $ (5,970) $ (4,368) $ (16,691)

BASIC EARNINGS (LOSS) PER ORDINARY SHARE $ 0.07 $ (0.22) $ (0.16) $ (0.63)

DILUTED EARNINGS (LOSS) PER ORDINARY SHARE $ 0.07 $ (0.22) $ (0.16) $ (0.63)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE 27,857,620 27,660,326 27,857,620 26,306,484

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE 27,857,620 27,660,326 27,857,620 26,306,484

X

- Definition
Financial expenses (income), net.
+ References
No definition available.
+ Details

Name: slgl_FinancialIncomeExpensesNet

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands

Ordinary shares [Member]

Additional Paid-In Capital [Member]

Accumulated deficit [Member]

Total

Balance at Dec. 31, 2022 $ 638 $ 234,640 $ (193,065) $ 42,213

Balance, shares at Dec. 31, 2022 23,129,469

Loss for the period (16,691) (16,691)

Issuance of shares and warrants through public offering, net of issuance costs $ 74 11,468 11,542

Issuance of shares and warrants through public offering, net of issuance costs Shares 2,560,000

Issuance of shares and warrants through private placement from the controlling shareholder $ 56 9,944 10,000

Issuance of shares and warrants through private placement from the controlling shareholder Shares 2,000,000

Exercise of options $ 3 177 180

Exercise of options, shares 116,485

Share-based compensation 1,052 1,052

Balance at Jun. 30, 2023 $ 771 257,281 (209,756) 48,296

Balance, shares at Jun. 30, 2023 27,805,954

Balance at Mar. 31, 2023 $ 712 246,678 (203,786) 43,604

Balance, shares at Mar. 31, 2023 25,702,237

Loss for the period (5,970) (5,970)

Issuance of shares and warrants through private placement from the controlling shareholder $ 56 9,944 10,000

Issuance of shares and warrants through private placement from the controlling shareholder Shares 2,000,000

Exercise of options $ 3 161 164

Exercise of options, shares 103,717

Share-based compensation 498 498

Balance at Jun. 30, 2023 $ 771 257,281 (209,756) 48,296

Balance, shares at Jun. 30, 2023 27,805,954

Balance at Dec. 31, 2023 $ 774 258,173 (220,303) $ 38,644

Balance, shares at Dec. 31, 2023 27,857,620 27,857,620

Loss for the period $ 0 (4,368) $ (4,368)

Share-based compensation 0 626 626

Balance at Jun. 30, 2024 $ 774 258,799 (224,671) $ 34,902

Balance, shares at Jun. 30, 2024 27,857,620 27,857,620

Balance at Mar. 31, 2024 $ 774 258,524 (226,647) $ 32,651

Balance, shares at Mar. 31, 2024 27,857,620

Loss for the period $ 0 1,976 1,976

Share-based compensation 0 275 275

Balance at Jun. 30, 2024 $ 774 $ 258,799 $ (224,671) $ 34,902

Balance, shares at Jun. 30, 2024 27,857,620 27,857,620

X

- Definition
Represents amount of issuance of shares and warrants through private placement.
+ References
No definition available.
+ Details

Name: slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents amount of issuance of shares and warrants through private placement, shares.
+ References
No definition available.
+ Details

Name: slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares

Namespace Prefix: slgl_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Issuance of shares and warrants through public offering, net of issuance costs.
+ References
No definition available.
+ Details

Name: slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Issuance of shares and warrants through public offering, net of issuance costs, shares
+ References
No definition available.
+ Details

Name: slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares

Namespace Prefix: slgl_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-2

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Dec. 31, 2023

CASH FLOWS FROM OPERATING ACTIVITIES:

Loss for the period $ 1,976 $ (5,970) $ (4,368) $ (16,691)

Adjustments required to reconcile loss to net cash used in operating activities:

Depreciation 125 185

Changes in accrued liability for employee rights upon retirement, net (10) 9

Share-based compensation expenses 275 498 626 1,052

Financial expenses (income), net (2) (1)

Net changes in operating leases (45) (36)

Changes in fair value of marketable securities (87) (66)

Changes in operating asset and liabilities:

Receivables from collaborative and licensing arrangements 0 5,653

Accounts receivables (5,682) 0

Prepaid expenses and other current assets 1,065 (1,063)

Accounts payable, accrued expenses and other 751 2,623

Net cash used in operating activities (7,627) (8,335)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment 0 (94)

Proceeds from sale of property and equipment 4 0

Investment in marketable securities 0 (17,114) $ (23,164)

Proceeds from sales and maturity of marketable securities 5,646 7,995 11,807

Short-term deposits 6,000 (1,000)

Long-term deposits 821 12

Net cash provided by (used in) investing activities 12,471 (10,201)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercise of options 0 180

Proceeds from issuance of shares and warrants through placement from the controlling shareholder 0 10,000

Proceeds from issuance of shares and warrants through public offering, net of issuance costs 0 11,542

Net cash provided by financing activities 0 21,722

EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS 2 1

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS 4,846 3,187

CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD 7,863 13,598 13,598

CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD 12,709 16,785 12,709 16,785 7,863

Cash and Cash equivalents 11,549 15,618 11,549 15,618 7,513

Restricted cash 1,160 1,167 1,160 1,167

CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS $ 12,709 $ 16,785 12,709 16,785 $ 7,863

SUPPLEMENTARY DISCLOSURE OF NON-CASH ACTIVITIES:

Recognition of new operating lease ROU and liabilities 0 190

SUPPLEMENTARY INFORMATION:

Interest received $ 1,121 $ 590

X

- Definition
Changes in accrued liability for employee rights upon retirement.
+ References
No definition available.
+ Details

Name: slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash inflow from changes in fair value of marketable securities.
+ References
No definition available.
+ Details

Name: slgl_ChangesInFairValueOfMarketableSecurities

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Finance expenses, net.
+ References
No definition available.
+ Details

Name: slgl_FinanceExpensesNet

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Net changes in operating leases.
+ References
No definition available.
+ Details

Name: slgl_NetChangesInOperatingLeases

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the amount of proceeds from long-term deposits.
+ References
No definition available.
+ Details

Name: slgl_ProceedsFromLongTermDeposits

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the amount of proceeds from short term deposits.
+ References
No definition available.
+ Details

Name: slgl_ProceedsFromShortTermDeposits

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount represents recognition ofoperating lease right of use assets and liabilities.
+ References
No definition available.
+ Details

Name: slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-SubTopic 230
-Topic 830
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477401/830-230-45-1
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 830
-SubTopic 230
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477401/830-230-45-1
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due within one year (or one business cycle) of receivables that were originally due beyond one year (or one business cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpensesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash outflow for purchase of marketable security.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481830/320-10-45-11
+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest received on loans and other debt instruments during the current period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-16
+ Details

Name: us-gaap_ProceedsFromInterestReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2A
-Subparagraph (a)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-2

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details

Name: us-gaap_RestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1

NATURE OF OPERATIONS
6 Months Ended

Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NOTE 1 - NATURE OF OPERATIONS

Sol-Gel Technologies Ltd. (collectively with its U.S. subsidiary, the Company) is an Israeli Company incorporated in 1997.

The Company is an innovative dermatology company with a successful track record of two NDA approvals and advanced orphan drugs pipeline. The Company has two approved drugs: (i) Twyneo®, which was developed for the treatment of acne vulgaris and received marketing authorization by the U.S. Food and Durg Administration (the "FDA") on July 27, 2021 and (ii) Epsolay®, a treatment for subtype II rosacea that received marketing authorization by the FDA on April 25, 2022. In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of Twyneo® and Epsolay® in the United States, see Note 6a. On April 14, 2022, the Company announced that Twyneo® is available for purchase by consumers who obtain a prescription from their physician. On June 2, 2022, the Company announced that Epsolay® is available for purchase by consumers who obtain a prescription from their physician. In addition to the novel products, the Company’s products included the approved generic products Acyclovir, Ivermectin and other generic product candidates. In November 2021, the Company entered into an agreement with Padagis, to sell its rights in relation to ten generic collaborative agreements between the parties, including the agreements for the two aforementioned approved generic drug products. Under the new agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, see note 5c.

On January 27, 2023 the Company entered into an asset purchase agreement ("APA") with PellePharm, Inc. (hereafter-“PellePharm”), pursuant to which the Company agreed to purchase all of the assets related to the topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome (such compound designated as investigational compound SGT-610). On January 30, 2023, upon closing of the transaction, the Company paid an upfront payment (hereafter- "upfront payment") of $4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date. In addition, the Company will be required to pay total development and NDA acceptance milestones of up to $6 million, and up to $64 million in commercial milestones which amount increases to $89 million when sales exceed $500 million as well as single digit royalties which increase to double digit royalties when sales exceed $500 million. During March 2024 the first developement milestone event has completed and the Company recorded an amount of $500 as clinical expenses.

The upfront payment and the additional development milestone payments under the APA represent payments for research and development in-process ("IPR&D") acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use. Accordingly, such payments were expensed as incurred and recognized as research and development expenses.

On May 15, 2024, the Company and Shenzhen Beimei Pharmaceutical Co. Ltd. ("Beimei"), entered into an asset purchase agreement, For further details, see Note 6c.

The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regards to marketing, regulatory affairs and business development relating to its products and technology in the U.S.

In October 2023, Hamas terrorists infiltrated Israel’s southern border and launched a series of attacks against Israel. Following these attacks, Israel’s security cabinet declared war against Hamas and initiated a military campaign. As of the issuance date of this report, there was no material impact on the Company's ongoing operations in Israel. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employee

Risk and Uncertainties

Since incorporation through June 30, 2024, the Company has an accumulated deficit of $224,671 and its activities have been funded mainly by its shareholders, collaboration revenues and license agreements, see also Notes 5 and 6. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations.

Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of June 30, 2024 will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/275/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1

SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:

a.
Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.

The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.

Earnings (Loss) per share

Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.

The calculation of diluted earnings per share, does not include 6,501,769 options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.

The calculation of diluted loss per share does not include 6,993,858 options and warrants for the six months ended June 30, 2024 and 5,961,999 and 7,120,463 options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.

b.

Recently issued accounting pronouncements, not yet adopted

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483426/235-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 235
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/235/tableOfContent
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1

MARKETABLE SECURITIES
6 Months Ended

Jun. 30, 2024

Investments, Debt and Equity Securities [Abstract]

MARKETABLE SECURITIES

NOTE 3 - MARKETABLE SECURITIES:

The following table sets forth the Company’s marketable securities for the indicated periods:

December 31,

June 30,

2023

2024

Level 2 securities:

U.S government and agency bonds

2,583

1,612

Other foreign government bonds

1,946

1,974

Corporate bonds*

15,942

11,326

Total

20,471

14,912

* Investments in Corporate bonds rated A or higher.

The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis.

The Company’s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.

The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the indicated periods:

Marketable securities

For the year ended

For the six months

December 31, 2023

ended June 30, 2024

Balance at beginning of the period

$

8,678

$

20,471

Additions

23,164

-

Sale or maturity

(11,807

)

(5,646

)

Changes in fair value during the period

436

87

Balance at end of the period

$

20,471

$

14,912

As of June 30, 2024, the Company’s debt securities had the following maturity dates:

Market value

June 30,

2024

Due within one year

$

14,912

The fair value of bank deposits approximates their carrying value, since they bear interest at rates close to the prevailing market rates. In addition, due to the short-term nature and/or low-risk nature of the Company's cash and cash equivalents, restricted cash equivalents, accounts receivable, accounts payable and other payables , their carrying amounts approximates their fair value

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 940
-SubTopic 320
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/940-320/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-K (SK)
-Number 229
-Section 1403
-Paragraph b
-Publisher SEC

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/320/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/942-320/tableOfContent
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1

REVENUE
6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

REVENUE

NOTE 4 - REVENUE:

The following table sets forth the Company’s revenues for the indicated periods:

Six months ended

June 30

Three months ended

June 30

2023

2024

2023

2024

Royalties revenue

$

514

$

1,056

$

214

$

612

Sale of IP and license revenue

380

4,800

380

4,800

Support services

-

43

-

21

Total revenue

$

894

$

5,899

$

594

$

5,433

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1

COLLABORATION AGREEMENTS
6 Months Ended

Jun. 30, 2024

Collaboration Agreements [Abstract]

COLLABORATION AGREEMENTS
NOTE 5 - COLLABORATION AGREEMENTS:

a.
In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales, royalties are not material.

b.
In 2016 through 2020, the Company entered into several collaboration agreements mainly with one third party (the "Partner") for the development, manufacturing and commercialization of several product candidates (including an agreement assumed by the Company in August 2018, following the transfer of an in-process research and development product candidate from a related party).

c.
Under the agreements, the Partner is obligated to conduct regulatory, scientific, clinical and technical activities necessary to develop the products and prepare and file an abbreviated new drug application ("ANDA"), with the FDA and gain regulatory approval. The Company participates in the development of the product candidates, including participation in joint steering committees and is obligated for sourcing the active pharmaceutical ingredient (API) during the development phase.

Upon FDA approval, the Partner has exclusive rights and is required to use diligent efforts to commercialize these products in territories defined under the agreements, including all required sales, marketing and distributing activities associated with the agreements. The Company is entitled to a share of the Partner's gross profits related to the sale of the products, as such term is defined in each of the agreements.

These Agreements are considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company recognizes collaboration revenues when the related sales occur.

In November 2021, the Company entered into a new agreement ("New Agreement") with the Partner, to sell its rights to the Partner in relation to ten generic collaborative agreements between the parties in consideration of $21,500 which was paid over 24 months. Under the New Agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, and is no longer entitled to receive its share in profit as detailed above.

In addition, the Company ceased paying any outstanding and future operational costs related to these collaborative agreements.

In August 15, 2024 the Company entered into a Termination Agreement with the Partner, For further details, see note 9.

X

- References
No definition available.
+ Details

Name: slgl_CollaborationAgreementsAbstract

Namespace Prefix: slgl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of collaboration agreements.
+ References
No definition available.
+ Details

Name: slgl_CollaborationAgreementsTextBlock

Namespace Prefix: slgl_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1

AGREEMENTS
6 Months Ended

Jun. 30, 2024

License Agreements [Abstract]

AGREEMENTS

NOTE 6 - AGREEMENTS:

a.
In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of two of the Company's most advanced investigational drug products (Twyneo® and Epsolay®) in the United States. The Company was entitled to amounts of up to $7.5 million per product in upfront payments and regulatory approval milestone payments assuming 2021 approval of each respective product. The Company is also eligible to receive tiered double-digit royalties ranging from mid-teen to high-teen percentage of net sales as well as up to $9 million in sales milestone payments.

According to the agreement, the Company has an option to regain commercialization rights five years following first commercialization.

On April 14, 2022, the Company announced that Twyneo® is available for purchase by consumers who obtain a prescription from their physician, See note 1. On June 2, 2022, the Company announced that Epsolay® is available for purchase by consumers who obtain a prescription from their physician, See also note 1. The Company recognized $723 and $466 during the six-month periods ended June 30, 2024 and 2023, respectively, as royalty revenue in respect of the license agreement for both products.

b.
On June 6, 2023, the Company and Searchlight Pharma Inc. (“Searchlight”), a private Canadian specialty pharmaceutical company, signed on an exclusive license agreements for Twyneo® and Epsolay® for the Canadian market, over a fifteen-year term that is renewable for subsequent five-year periods. Searchlight will be responsible for obtaining and maintaining any regulatory approvals required to market and sell the drugs in Canada, with support from the Company.

Under the agreement, the Company will receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined. In addition, the Company will be entitled to royalty percentages of all Canadian net sales ranging from low-double-digits to high teens.

In June 2023, the Company received $500 as an upfront payment in connection with the license agreement and related support provided to Searchlight for obtaining the regulatory approval in the Canadian market. The Company is also required to support Searchlight during such period if needed based on agreed upon rates. The Company has identified two performance obligations in the license agreement as follows: (i) the license to market the products in Canada; and (ii) continuing support during the regulatory approval process.

For the six-month period ended June 30, 2024, the Company recognized a total amount of $42 for continuing support. The remaining outstanding contract liability in respect of the support services, is, as of June 30, 2024 $78 .

c.
On May 15, 2024, the Company and Beimei, a private Chinese company, signed an agreement for the purchase and license by Beimei of certain rights in the intellectual property ("IP") related to Twyneo, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.

Under the terms of the agreement, Beimei will purchase and license from the Company the IP in these territories. The Company is also required to support Beimei to a certain extent during the period until obtaining regulatory approval. The Company may provide further support services to Beimei, if needed, based on agreed upon rates. In return, Sol-Gel is to receive payments of up to $10 million (including amounts contingent on achieving certain milestones) and up to $5 million as royalty payments on net sales.

The Company has identified multiple performance obligations in the agreement. Revenue from sale and license of IP is recognized at a point in time, upon transfer of control over the license and the IP to Beimei. Support services are recognized over time as the services are performed.

For the six-month period ended June 30, 2024, the Company recognized revenue for a total amount of $4.8 million. This amount does not include variable consideration that was determined to be constrained (not probable that would not result in a significant reversal). In addition, the Company recorded $200 as a contract liability in respect of the support services.

In July 2024, the Company received $2 million as the first payment in connection with the agreement.

X

- References
No definition available.
+ Details

Name: slgl_LicenseAgreementsAbstract

Namespace Prefix: slgl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for license agreements information.
+ References
No definition available.
+ Details

Name: slgl_LicenseAgreementsTextBlock

Namespace Prefix: slgl_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1

SHARE BASED COMPENSATION
6 Months Ended

Jun. 30, 2024

Stockholders' Equity Note [Abstract]

SHARE BASED COMPENSATION

NOTE 7 - SHARE BASED COMPENSATION:

During the six months ended June 30, 2024, the Company granted 300,000 options to Directors as follows:

In January 2024, the board of directors approved and recommended the Company's shareholders to approve a grant of 300,000 options to the Company's Directors to purchase ordinary shares at an exercise price of $1.2 per share. The Company's shareholders approved the grant in February 28, 2024.

The options vest over a period of 3 years; one third of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over the following two years. The options expire on the tenth anniversary of their grant date.

The fair value of options granted in 2024 was $207. The underlying data used for computing the fair value of the options are as follows:

2024

Value of one ordinary share

$

1.2

Dividend yield

0

%

Expected volatility

72

%

Risk-free interest rate

4.8

%

Expected term

4 years

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1

RELATED PARTIES
6 Months Ended

Jun. 30, 2024

Related Party Transactions [Abstract]

RELATED PARTIES

NOTE 8 - RELATED PARTIES:

a.
Related parties include the controlling shareholder and companies under his control, the board of directors and the executive officers of the Company.

b.
As to options granted to directors and executive officers, see note 7.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1

SUBSEQUENT EVENT
6 Months Ended

Jun. 30, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENT

NOTE 9 – SUBSEQUENT EVENT

In August 15, 2024, the Company entered into a Termination Agreement ("the Agreement") with the Partner. The purpose of the Agreement is to terminate the Development, Manufacturing and Commercialization Agreement dated June 28, 2020, and to sell its rights to the Partner in relation to Roflumilast cream and Roflumilast foam. As consideration for the Agreement between the parties, the Partner will pay to the Company $4,250, which will paid in quarterly installments during 24 months. In addition, in the end of each quarter for five years as of the Launch Date (the date of first commercial sale of the Product in the Territory by the Partner or its Affiliates pursuant to the ANDA), the Partner shall pay Sol-Gel 2% royalties of the Partner’s Gross Profits for that Product.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1

SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Basis of Presentation

a.
Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.

The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.

Earnings (Loss) per share

Earnings (Loss) per share

Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.

The calculation of diluted earnings per share, does not include 6,501,769 options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.

The calculation of diluted loss per share does not include 6,993,858 options and warrants for the six months ended June 30, 2024 and 5,961,999 and 7,120,463 options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.

Recently issued accounting pronouncements, not yet adopted

b.

Recently issued accounting pronouncements, not yet adopted

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-2
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1

MARKETABLE SECURITIES (Tables)
6 Months Ended

Jun. 30, 2024

Investments, Debt and Equity Securities [Abstract]

Schedule of Marketable Securities

December 31,

June 30,

2023

2024

Level 2 securities:

U.S government and agency bonds

2,583

1,612

Other foreign government bonds

1,946

1,974

Corporate bonds*

15,942

11,326

Total

20,471

14,912

* Investments in Corporate bonds rated A or higher.

Schedule of Summary of Changes in Fair Value of Marketable Securities

Marketable securities

For the year ended

For the six months

December 31, 2023

ended June 30, 2024

Balance at beginning of the period

$

8,678

$

20,471

Additions

23,164

-

Sale or maturity

(11,807

)

(5,646

)

Changes in fair value during the period

436

87

Balance at end of the period

$

20,471

$

14,912

Schedule of Debt Securities

Market value

June 30,

2024

Due within one year

$

14,912

X

- Definition
Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.
+ References
No definition available.
+ Details

Name: us-gaap_MarketableSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of derivative assets at fair value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1

REVENUE (Tables)
6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Components of Revenues

Six months ended

June 30

Three months ended

June 30

2023

2024

2023

2024

Royalties revenue

$

514

$

1,056

$

214

$

612

Sale of IP and license revenue

380

4,800

380

4,800

Support services

-

43

-

21

Total revenue

$

894

$

5,899

$

594

$

5,433

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1

SHARE BASED COMPENSATION (Tables)
6 Months Ended

Jun. 30, 2024

Stockholders' Equity Note [Abstract]

Schedule of Assumptions Used to Estimate Fair Value

2024

Value of one ordinary share

$

1.2

Dividend yield

0

%

Expected volatility

72

%

Risk-free interest rate

4.8

%

Expected term

4 years

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (f)(2)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1

NATURE OF OPERATIONS (Narrative) (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended

Jan. 30, 2023

Mar. 31, 2024

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Dec. 31, 2023

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Accumulated deficit $ (224,671) $ (224,671) $ (220,303)

Sales amount $ 5,433 $ 594 $ 5,899 $ 894

PellePharm, Inc. [Member] | Asset Purchase Agreement [Member] | Development And Nda Acceptance Milestones [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Sales milestone payments $ 6,000

PellePharm, Inc. [Member] | Asset Purchase Agreement [Member] | Commercial Milestones [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Sales milestone payments $ 64,000

Description of upfront payment $4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date.

Increase in sales milestone amount due to sales exceed dollar 500 million $ 89,000

Sales amount $ 500,000

Clinical expenses $ 500

X

- Definition
The amount of clinical expenses during the period.
+ References
No definition available.
+ Details

Name: slgl_ClinicalExpenses

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description of upfront payment.
+ References
No definition available.
+ Details

Name: slgl_DescriptionOfUpfrontPayment

Namespace Prefix: slgl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the Increase in Sales Milestone amount due to sales exceed dollar 500 million.
+ References
No definition available.
+ Details

Name: slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represent of amount the sales milestone payments
+ References
No definition available.
+ Details

Name: slgl_SalesMilestonePayments

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated undistributed earnings (deficit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AssetAcquisitionAxis=slgl_PellepharmMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=slgl_AssetPurchaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: slgl_MilestonePaymentsAxis=slgl_DevelopmentAndNdaAcceptanceMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: slgl_MilestonePaymentsAxis=slgl_CommercialMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - shares
3 Months Ended 6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Options and Warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities excluded from computation 6,501,769 7,120,463 6,993,858 5,961,999

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1

MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details) - USD ($)
$ in Thousands

Jun. 30, 2024

Dec. 31, 2023

Dec. 31, 2022

Level 2 securities:

Marketable securities $ 14,912 $ 20,471 $ 8,678

U.S government and agency bonds [Member]

Level 2 securities:

Marketable securities 1,612 2,583

Other foreign government bonds [Member]

Level 2 securities:

Marketable securities 1,974 1,946

Corporate bonds [Member]

Level 2 securities:

Marketable securities ^[1] $ 11,326 $ 15,942

[1] Investments in Corporate bonds rated A or higher.

X

- References
No definition available.
+ Details

Name: us-gaap_MarketableSecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in marketable security, classified as current.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=slgl_OtherForeignGovernmentBondsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1

MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Dec. 31, 2023

Investments, Debt and Equity Securities [Abstract]

Balance at beginning of the period $ 20,471 $ 8,678 $ 8,678

Additions 0 17,114 23,164

Sale or maturity (5,646) $ (7,995) (11,807)

Changes in fair value during the period 87 (436)

Balance at end of the period $ 14,912 $ 20,471

X

- Definition
Amount of increase (decrease) of investment in debt and equity securities, measured at fair value with changes in fair value recognized in net income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-19
+ Details

Name: us-gaap_IncreaseDecreaseInTradingSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in marketable security, classified as current.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash outflow for purchase of marketable security.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481830/320-10-45-11
+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1

MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)
$ in Thousands

Jun. 30, 2024

USD ($)

Investments, Debt and Equity Securities [Abstract]

Due within one year $ 14,912

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1

REVENUE (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Total revenue $ 5,433 $ 594 $ 5,899 $ 894

Royalties revenue [Member]

Total revenue 612 214 1,056 514

Sale of IP and license revenue [Member]

Total revenue 4,800 380 4,800 380

Support services [Member]

Total revenue $ 21 $ 0 $ 43 $ 0

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ServiceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1

COLLABORATION AGREEMENTS (Narrative) (Details)
$ in Thousands
12 Months Ended

Dec. 31, 2007

Nov. 01, 2021

USD ($)

Agreement

Candidate

Program

Number of generic collaborative agreements to sell rights | Agreement 10

Number of generic programs retained for collaboration rights | Program 2

Number of generic drug candidates | Candidate 4

Expected revenue receivable over twenty four months | $ $ 21,500

Minimum [Member]

Royalties maturity 2016

Maximum [Member]

Royalties maturity 2024

X

- Definition
Represents the value of expected revenue receivable over twenty four months.
+ References
No definition available.
+ Details

Name: slgl_ExpectedRevenueReceivableOverTwentyFourMonths

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of generic collaborative agreements to sell the rights.
+ References
No definition available.
+ Details

Name: slgl_NumberOfGenericCollaborativeAgreementsToSellRights

Namespace Prefix: slgl_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of generic drug candidates.
+ References
No definition available.
+ Details

Name: slgl_NumberOfGenericDrugCandidates

Namespace Prefix: slgl_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of generic programs retained for collaboration rights.
+ References
No definition available.
+ Details

Name: slgl_NumberOfGenericProgramsRetainedForCollaborationRights

Namespace Prefix: slgl_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Royalties Maturity.
+ References
No definition available.
+ Details

Name: slgl_RoyaltiesMaturity

Namespace Prefix: slgl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1

AGREEMENTS (Narrative) (Details) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended

Jun. 06, 2023

Jun. 30, 2021

Jun. 30, 2024

Jun. 30, 2023

Twyneo [Member] | License Agreements With Galderma [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Regulatory approval milestone payments received $ 7,500

Twyneo [Member] | License Agreements With Beimei [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Sales milestone payments $ 2,000

Upfront payments received 10,000

Royalties revenues 5,000

Contract liability 200

Estimated variable consideration 4,800

Twyneo And Epsolay [Member] | License Agreements With Galderma [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Sales milestone payments $ 9,000

Royalties revenues 723 $ 466

Twyneo And Epsolay [Member] | License Agreements With Searchlight [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Upfront payments received $ 11,000 $ 500

Royalties revenues 42

Contract liability $ 78

X

- Definition
Information about contract liability.
+ References
No definition available.
+ Details

Name: slgl_ContractLiability

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the amount of revenue that is estimated variable consideration.
+ References
No definition available.
+ Details

Name: slgl_EstimatedVariableConsiderationRevenue

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Regulatory approval milestone payments received.
+ References
No definition available.
+ Details

Name: slgl_RegulatoryApprovalMilestonePaymentsReceived

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represent of amount the sales milestone payments
+ References
No definition available.
+ Details

Name: slgl_SalesMilestonePayments

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Upfront payments received.
+ References
No definition available.
+ Details

Name: slgl_UpfrontPaymentsReceived

Namespace Prefix: slgl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=slgl_TwyneoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=slgl_LicenseAgreementsWithGaldermaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=slgl_LicenseAgreementsWithBeimeiMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=slgl_TwyneoAndEpsolayMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=slgl_LicenseAgreementsWithSearchlightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1

SHARE BASED COMPENSATION (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 6 Months Ended

Jan. 31, 2024

Jun. 30, 2024

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of options granted $ 207

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Option grants 300,000 300,000

Exercise price $ 1.2

Option vesting period 3 years

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_TitleOfIndividualAxis=srt_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1

SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)
6 Months Ended

Jun. 30, 2024

$ / shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Value of one ordinary share $ 1.2

Dividend yield 0.00%

Expected volatility 72.00%

Risk-free interest rate 4.80%

Expected term 4 years

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1

SUBSEQUENT EVENT (Narrative) (Details) - Subsequent Event [Member] - Partner [Member]
$ in Thousands

Aug. 15, 2024

USD ($)

Subsequent Event [Line Items]

Consideration for agreement $ 4,250

Royalties percentage 2.00%

X

- Definition
The information about the royalties percentage.
+ References
No definition available.
+ Details

Name: slgl_RoyaltiesPercentage

Namespace Prefix: slgl_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of transactions with related party during the financial reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-3
+ Details

Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_GeneralPartnerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 81 132 1 true 24 0 false 8 false false R1.htm 0001 - Document - Document and Entity Information Sheet http://www.sol-gel.co/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) Sheet http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 0007 - Disclosure - NATURE OF OPERATIONS Sheet http://www.sol-gel.co/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.sol-gel.co/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 0009 - Disclosure - MARKETABLE SECURITIES Sheet http://www.sol-gel.co/role/MarketableSecurities MARKETABLE SECURITIES Notes 9 false false R10.htm 0010 - Disclosure - REVENUE Sheet http://www.sol-gel.co/role/REVENUE REVENUE Notes 10 false false R11.htm 0011 - Disclosure - COLLABORATION AGREEMENTS Sheet http://www.sol-gel.co/role/CollaborationAgreements COLLABORATION AGREEMENTS Notes 11 false false R12.htm 0012 - Disclosure - AGREEMENTS Sheet http://www.sol-gel.co/role/LicenseAgreements AGREEMENTS Notes 12 false false R13.htm 0013 - Disclosure - SHARE BASED COMPENSATION Sheet http://www.sol-gel.co/role/ShareCapital SHARE BASED COMPENSATION Notes 13 false false R14.htm 0014 - Disclosure - RELATED PARTIES Sheet http://www.sol-gel.co/role/RelatedParties RELATED PARTIES Notes 14 false false R15.htm 0015 - Disclosure - SUBSEQUENT EVENT Sheet http://www.sol-gel.co/role/SUBSEQUENTEVENTS SUBSEQUENT EVENT Notes 15 false false R16.htm 0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 0017 - Disclosure - MARKETABLE SECURITIES (Tables) Sheet http://www.sol-gel.co/role/MarketableSecuritiesTables MARKETABLE SECURITIES (Tables) Tables http://www.sol-gel.co/role/MarketableSecurities 17 false false R18.htm 0018 - Disclosure - REVENUE (Tables) Sheet http://www.sol-gel.co/role/REVENUETables REVENUE (Tables) Tables http://www.sol-gel.co/role/REVENUE 18 false false R19.htm 0019 - Disclosure - SHARE BASED COMPENSATION (Tables) Sheet http://www.sol-gel.co/role/ShareCapitalTables SHARE BASED COMPENSATION (Tables) Tables http://www.sol-gel.co/role/ShareCapital 19 false false R20.htm 0020 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details) Sheet http://www.sol-gel.co/role/NatureOfOperationsDetails NATURE OF OPERATIONS (Narrative) (Details) Details http://www.sol-gel.co/role/NatureOfOperations 20 false false R21.htm 0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Sheet http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Details http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies 21 false false R22.htm 0022 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details) Sheet http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details) Details http://www.sol-gel.co/role/MarketableSecuritiesTables 22 false false R23.htm 0023 - Disclosure - MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details) Sheet http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details) Details http://www.sol-gel.co/role/MarketableSecuritiesTables 23 false false R24.htm 0024 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details) Sheet http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details) Details http://www.sol-gel.co/role/MarketableSecuritiesTables 24 false false R25.htm 0025 - Disclosure - REVENUE (Details) Sheet http://www.sol-gel.co/role/REVENUEDetails REVENUE (Details) Details http://www.sol-gel.co/role/REVENUETables 25 false false R26.htm 0026 - Disclosure - COLLABORATION AGREEMENTS (Narrative) (Details) Sheet http://www.sol-gel.co/role/CollaborationAgreementsDetails COLLABORATION AGREEMENTS (Narrative) (Details) Details http://www.sol-gel.co/role/CollaborationAgreements 26 false false R27.htm 0027 - Disclosure - AGREEMENTS (Narrative) (Details) Sheet http://www.sol-gel.co/role/LicenseAgreementsDetails AGREEMENTS (Narrative) (Details) Details http://www.sol-gel.co/role/LicenseAgreements 27 false false R28.htm 0028 - Disclosure - SHARE BASED COMPENSATION (Narrative) (Details) Sheet http://www.sol-gel.co/role/ShareCapitalNarrativeDetails SHARE BASED COMPENSATION (Narrative) (Details) Details http://www.sol-gel.co/role/ShareCapitalTables 28 false false R29.htm 0029 - Disclosure - SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details) Sheet http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details) Details http://www.sol-gel.co/role/ShareCapitalTables 29 false false R30.htm 0030 - Disclosure - SUBSEQUENT EVENT (Narrative) (Details) Sheet http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails SUBSEQUENT EVENT (Narrative) (Details) Details http://www.sol-gel.co/role/SUBSEQUENTEVENTS 30 false false All Reports Book All Reports exhibit_99-2.htm zk2431829.htm slgl-20240630.xsd slgl-20240630_cal.xml slgl-20240630_def.xml slgl-20240630_lab.xml slgl-20240630_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "exhibit_99-2.htm zk2431829.htm": { "nsprefix": "slgl", "nsuri": "http://www.sol-gel.co/20240630", "dts": { "inline": { "local": [ "exhibit_99-2.htm", "zk2431829.htm" ] }, "schema": { "local": [ "slgl-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "slgl-20240630_cal.xml" ] }, "definitionLink": { "local": [ "slgl-20240630_def.xml" ] }, "labelLink": { "local": [ "slgl-20240630_lab.xml" ] }, "presentationLink": { "local": [ "slgl-20240630_pre.xml" ] } }, "keyStandard": 104, "keyCustom": 28, "axisStandard": 10, "axisCustom": 1, "memberStandard": 14, "memberCustom": 10, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2024": 6 }, "contextCount": 81, "entityCount": 1, "segmentCount": 24, "elementCount": 235, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 290, "http://xbrl.sec.gov/dei/2024": 13 }, "report": { "R1": { "role": "http://www.sol-gel.co/role/DocumentAndEntityInformation", "longName": "0001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "dei:DocumentFiscalYearFocus", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431829.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "dei:DocumentFiscalYearFocus", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431829.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets", "longName": "0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_20240630", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240630", "name": "us-gaap:DepositsAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "unique": true } }, "R3": { "role": "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_20240630", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "ILSPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240630", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "ILSPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations", "longName": "0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_20240401to20240630", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240401to20240630", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "unique": true } }, "R5": { "role": "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "longName": "0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows", "longName": "0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_20240401to20240630", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "unique": true } }, "R7": { "role": "http://www.sol-gel.co/role/NatureOfOperations", "longName": "0007 - Disclosure - NATURE OF OPERATIONS", "shortName": "NATURE OF OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.sol-gel.co/role/SignificantAccountingPolicies", "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.sol-gel.co/role/MarketableSecurities", "longName": "0009 - Disclosure - MARKETABLE SECURITIES", "shortName": "MARKETABLE SECURITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.sol-gel.co/role/REVENUE", "longName": "0010 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.sol-gel.co/role/CollaborationAgreements", "longName": "0011 - Disclosure - COLLABORATION AGREEMENTS", "shortName": "COLLABORATION AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "slgl:CollaborationAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "slgl:CollaborationAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.sol-gel.co/role/LicenseAgreements", "longName": "0012 - Disclosure - AGREEMENTS", "shortName": "AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "slgl:LicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "slgl:LicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.sol-gel.co/role/ShareCapital", "longName": "0013 - Disclosure - SHARE BASED COMPENSATION", "shortName": "SHARE BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.sol-gel.co/role/RelatedParties", "longName": "0014 - Disclosure - RELATED PARTIES", "shortName": "RELATED PARTIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.sol-gel.co/role/SUBSEQUENTEVENTS", "longName": "0015 - Disclosure - SUBSEQUENT EVENT", "shortName": "SUBSEQUENT EVENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies", "longName": "0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.sol-gel.co/role/MarketableSecuritiesTables", "longName": "0017 - Disclosure - MARKETABLE SECURITIES (Tables)", "shortName": "MARKETABLE SECURITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.sol-gel.co/role/REVENUETables", "longName": "0018 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.sol-gel.co/role/ShareCapitalTables", "longName": "0019 - Disclosure - SHARE BASED COMPENSATION (Tables)", "shortName": "SHARE BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.sol-gel.co/role/NatureOfOperationsDetails", "longName": "0020 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details)", "shortName": "NATURE OF OPERATIONS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "C_20240630", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230130to20230130_slglMilestonePaymentsAxis_slglDevelopmentAndNdaAcceptanceMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember", "name": "slgl:SalesMilestonePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "span", "div", "div", "div", "div", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "unique": true } }, "R21": { "role": "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails", "longName": "0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "C_20240401to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240401to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails", "longName": "0022 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)", "shortName": "MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "C_20240630", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240630_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:MarketableSecuritiesTextBlock", "div", "div", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "unique": true } }, "R23": { "role": "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails", "longName": "0023 - Disclosure - MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details)", "shortName": "MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:IncreaseDecreaseInTradingSecurities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "div", "div", "div", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "unique": true } }, "R24": { "role": "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails", "longName": "0024 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)", "shortName": "MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "C_20240630", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "div", "div", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240630", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "div", "div", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.sol-gel.co/role/REVENUEDetails", "longName": "0025 - Disclosure - REVENUE (Details)", "shortName": "REVENUE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_20240401to20240630", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240401to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "unique": true } }, "R26": { "role": "http://www.sol-gel.co/role/CollaborationAgreementsDetails", "longName": "0026 - Disclosure - COLLABORATION AGREEMENTS (Narrative) (Details)", "shortName": "COLLABORATION AGREEMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_20211101", "name": "slgl:NumberOfGenericCollaborativeAgreementsToSellRights", "unitRef": "Agreement", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "div", "div", "div", "slgl:CollaborationAgreementsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20211101", "name": "slgl:NumberOfGenericCollaborativeAgreementsToSellRights", "unitRef": "Agreement", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "div", "div", "div", "slgl:CollaborationAgreementsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.sol-gel.co/role/LicenseAgreementsDetails", "longName": "0027 - Disclosure - AGREEMENTS (Narrative) (Details)", "shortName": "AGREEMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember", "name": "slgl:RegulatoryApprovalMilestonePaymentsReceived", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "slgl:LicenseAgreementsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember", "name": "slgl:RegulatoryApprovalMilestonePaymentsReceived", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "slgl:LicenseAgreementsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails", "longName": "0028 - Disclosure - SHARE BASED COMPENSATION (Narrative) (Details)", "shortName": "SHARE BASED COMPENSATION (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20240630", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails", "longName": "0029 - Disclosure - SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)", "shortName": "SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_20240630", "name": "us-gaap:SharePrice", "unitRef": "USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240630", "name": "us-gaap:SharePrice", "unitRef": "USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails", "longName": "0030 - Disclosure - SUBSEQUENT EVENT (Narrative) (Details)", "shortName": "SUBSEQUENT EVENT (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_99-2.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r399" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivables", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r435" ] }, "us-gaap_AccountsReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Other long-term receivables", "verboseLabel": "Other long-term assets", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent." } } }, "auth_ref": [ "r253", "r435" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r24" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r289", "r425", "r426", "r427", "r428", "r449", "r498" ] }, "slgl_AdditionalRevenueContingentOnAchievingCertainMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "AdditionalRevenueContingentOnAchievingCertainMilestones", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Additional Revenue Contingent On Achieving Certain Milestones", "documentation": "Represents the amount of additional revenue contingent on achieving certain milestones.", "terseLabel": "Additional revenue contingent on achieving certain milestones" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments required to reconcile loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllOtherCorporateBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherCorporateBondsMember", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Corporate bonds [Member]", "documentation": "Investments in corporate fixed maturity debt securities classified as other." } } }, "auth_ref": [ "r500" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive shares", "terseLabel": "Anti-dilutive securities excluded from computation", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r96" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r10" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails", "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r204" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r117", "r118", "r119", "r120", "r121", "r448" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r117", "r118", "r119", "r120", "r121", "r448" ] }, "slgl_AssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "AssetPurchaseAgreementMember", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "The member stands for Asset Purchase Agreement.", "label": "Asset Purchase Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Default Label]", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r42", "r50", "r60", "r74", "r99", "r101", "r105", "r106", "r114", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r206", "r210", "r225", "r258", "r319", "r383", "r384", "r399", "r415", "r443", "r444", "r454" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r57", "r61", "r74", "r114", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r206", "r210", "r225", "r399", "r443", "r444", "r454" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent", "totalLabel": "TOTAL NON-CURRENT ASSETS", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r74", "r114", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r206", "r210", "r225", "r443", "r444", "r454" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS:" } } }, "auth_ref": [] }, "slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in two fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value", "verboseLabel": "Between 1-2 years" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Due within one year", "terseLabel": "Due within one year", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r113", "r256" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of presentation", "verboseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets", "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and Cash equivalents", "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r9", "r59", "r378" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS", "totalLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r9", "r33", "r71" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r33" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "verboseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:", "terseLabel": "SUPPLEMENTARY DISCLOSURE OF NON-CASH ACTIVITIES:" } } }, "auth_ref": [] }, "slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "ChangesInAccruedLiabilityForEmployeeRightsUponRetirement", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 80.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Changes in accrued liability for employee rights upon retirement.", "negatedLabel": "Changes in accrued liability for employee rights upon retirement, net", "label": "Changes In Accrued Liability For Employee Rights Upon Retirement" } } }, "auth_ref": [] }, "slgl_ChangesInFairValueOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "ChangesInFairValueOfMarketableSecurities", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 90.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Cash inflow from changes in fair value of marketable securities.", "negatedLabel": "Changes in fair value of marketable securities", "label": "Changes In Fair Value Of Marketable Securities", "terseLabel": "Change in fair value during the period" } } }, "auth_ref": [] }, "slgl_ClinicalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "ClinicalExpenses", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Clinical Expenses", "documentation": "The amount of clinical expenses during the period.", "terseLabel": "Clinical expenses" } } }, "auth_ref": [] }, "slgl_CollaborationAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "CollaborationAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Collaboration Agreements [Abstract]" } } }, "auth_ref": [] }, "slgl_CollaborationAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "CollaborationAgreementsTextBlock", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreements" ], "lang": { "en-us": { "role": { "label": "Collaboration Agreements [Text Block]", "documentation": "The entire disclosure of collaboration agreements.", "terseLabel": "COLLABORATION AGREEMENTS" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails", "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r204" ] }, "slgl_CommercialMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "CommercialMilestonesMember", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Commercial Milestones.", "label": "Commercial Milestones [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 20.0 } }, "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r20", "r43", "r259", "r306" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Ordinary shares [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r405", "r406", "r407", "r409", "r410", "r411", "r412", "r425", "r426", "r428", "r449", "r496", "r498" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Par value", "verboseLabel": "Ordinary shares, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r23" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r23", "r307" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r23" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "label": "Ordinary shares, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r23", "r307", "r325", "r498", "r499" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Ordinary Shares, NIS 0.1 par value - authorized: 50,000,000 as of December 31, 2021 and June 30, 2022; issued and outstanding: 23,000,782 and 23,029,951 as of December 31, 2021 and June 30, 2022, respectively.", "terseLabel": "Ordinary Shares, NIS 0.1 par value \u2013 authorized: 50,000,000 as of December 31, 2022 and June 30, 2023; issued and outstanding: 23,129,469 and 27,805,954 as of December 31, 2022 and June 30, 2023, respectively.", "verboseLabel": "Ordinary Shares, NIS 0.1 par value \u2013 authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of December 31, 2023 and June 30, 2024.", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r23", "r260", "r399" ] }, "slgl_ContractLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "ContractLiability", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information about contract liability.", "label": "Contract Liability", "terseLabel": "Contract liability" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liability for employee rights upon retirement", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r158" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Funds in respect of employee rights upon retirement", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r159", "r161", "r162", "r163", "r388", "r389", "r390" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Bank deposits", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r419" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r3", "r12" ] }, "slgl_DescriptionOfUpfrontPayment": { "xbrltype": "stringItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "DescriptionOfUpfrontPayment", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of upfront payment.", "label": "Description Of Upfront Payment", "terseLabel": "Description of upfront payment" } } }, "auth_ref": [] }, "slgl_DevelopmentAndNdaAcceptanceMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "DevelopmentAndNdaAcceptanceMilestonesMember", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Development And Nda Acceptance Milestones.", "label": "Development And Nda Acceptance Milestones [Member]" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r434", "r497" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.sol-gel.co/role/REVENUETables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Components of Revenues", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r446" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "BASIC LOSS PER ORDINARY SHARE", "verboseLabel": "BASIC EARNINGS (LOSS) PER ORDINARY SHARE", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r68", "r80", "r81", "r82", "r83", "r84", "r85", "r89", "r91", "r93", "r94", "r95", "r98", "r200", "r203", "r220", "r221", "r254", "r267", "r380" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "BASIC AND DILUTED LOSS PER ORDINARY SHARE", "terseLabel": "DILUTED LOSS PER ORDINARY SHARE", "verboseLabel": "DILUTED EARNINGS (LOSS) PER ORDINARY SHARE", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r68", "r80", "r81", "r82", "r83", "r84", "r85", "r91", "r93", "r94", "r95", "r98", "r200", "r203", "r220", "r221", "r254", "r267", "r380" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Loss per share", "terseLabel": "Earnings (Loss) per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r10", "r11", "r97" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r452" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r416" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.sol-gel.co/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r416" ] }, "slgl_EpsolayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "EpsolayMember", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Epsolay", "label": "Epsolay [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r55", "r64", "r65", "r66", "r75", "r76", "r77", "r79", "r84", "r86", "r88", "r100", "r115", "r116", "r122", "r148", "r195", "r196", "r197", "r198", "r199", "r201", "r202", "r203", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r239", "r266", "r277", "r278", "r279", "r289", "r347" ] }, "slgl_EstimatedVariableConsiderationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "EstimatedVariableConsiderationRevenue", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Estimated Variable Consideration Revenue", "documentation": "Represents the amount of revenue that is estimated variable consideration.", "terseLabel": "Estimated variable consideration" } } }, "auth_ref": [] }, "slgl_ExpectedRevenueReceivableOverTwentyFourMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "ExpectedRevenueReceivableOverTwentyFourMonths", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the value of expected revenue receivable over twenty four months.", "label": "Expected Revenue Receivable Over Twenty Four Months", "terseLabel": "Expected revenue receivable over twenty four months" } } }, "auth_ref": [] }, "slgl_FinanceExpensesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "FinanceExpensesNet", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Finance expenses, net.", "label": "Finance Expenses Net", "terseLabel": "Financial expenses (income), net" } } }, "auth_ref": [] }, "slgl_FinancialIncomeExpensesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "FinancialIncomeExpensesNet", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Financial expenses (income), net.", "negatedLabel": "FINANCIAL INCOME, net", "label": "Financial Income Expenses Net", "terseLabel": "FINANCIAL INCOME, net" } } }, "auth_ref": [] }, "us-gaap_ForeignGovernmentDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignGovernmentDebtMember", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Canada government bonds [Member]", "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity." } } }, "auth_ref": [ "r437", "r438" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "GENERAL AND ADMINISTRATIVE EXPENSES", "label": "GENERAL AND ADMINISTRATIVE EXPENSES", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r30", "r329" ] }, "us-gaap_GeneralPartnerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralPartnerMember", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "General Partner [Member]", "terseLabel": "Partner [Member]", "documentation": "Party to a partnership business who has unlimited liability." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Accounts receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable, accrued expenses and other", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInLongTermReceivablesCurrent", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Receivables from collaborative and licensing arrangements", "label": "Increase (Decrease) in Long-Term Receivables, Current", "documentation": "The increase (decrease) during the reporting period in the amount due within one year (or one business cycle) of receivables that were originally due beyond one year (or one business cycle)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating asset and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 60.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInTradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInTradingSecurities", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Changes in fair value of marketable securities", "label": "Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Changes in fair value during the period", "totalLabel": "Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI, Total", "documentation": "Amount of increase (decrease) of investment in debt and equity securities, measured at fair value with changes in fair value recognized in net income." } } }, "auth_ref": [ "r2", "r8" ] }, "slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the Increase in Sales Milestone amount due to sales exceed dollar 500 million.", "label": "Increase In Sales Milestone Amount Due To Sales Exceed Dollar 500 Million", "terseLabel": "Increase in sales milestone amount due to sales exceed dollar 500 million" } } }, "auth_ref": [] }, "slgl_IntellectualPropertyRelatedToTwyneoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "IntellectualPropertyRelatedToTwyneoMember", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Intellectual Property Related To Twyneo [Member]", "documentation": "This member stands for Intellectual Property Related To Twyneo." } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r292", "r293", "r294", "r295", "r296", "r354", "r356", "r358", "r361", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r407" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r292", "r293", "r294", "r295", "r296", "r354", "r356", "r358", "r361", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r407" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt Securities", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.sol-gel.co/role/MarketableSecurities" ], "lang": { "en-us": { "role": { "label": "MARKETABLE SECURITIES", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r46", "r54", "r111", "r112", "r223", "r224", "r463" ] }, "slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of issuance of shares and warrants through private placement.", "label": "Issuance Of Shares And Warrants Through Private Placement From Controlling Shareholder", "terseLabel": "Issuance of shares and warrants through private placement from the controlling shareholder" } } }, "auth_ref": [] }, "slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of issuance of shares and warrants through private placement, shares.", "label": "Issuance Of Shares And Warrants Through Private Placement From Controlling Shareholder Shares", "terseLabel": "Issuance of shares and warrants through private placement from the controlling shareholder Shares" } } }, "auth_ref": [] }, "slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Issuance of shares and warrants through public offering, net of issuance costs.", "label": "Issuance Of Shares And Warrants Through Public Offering Net Of Issuance Costs", "terseLabel": "Issuance of shares and warrants through public offering, net of issuance costs" } } }, "auth_ref": [] }, "slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Issuance of shares and warrants through public offering, net of issuance costs, shares", "label": "Issuance of shares and warrants through public offering, net of issuance costs, shares", "terseLabel": "Issuance of shares and warrants through public offering, net of issuance costs Shares" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r237" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r7", "r15", "r16", "r17", "r18", "r19", "r20", "r21", "r74", "r114", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r207", "r210", "r211", "r225", "r305", "r381", "r415", "r443", "r454", "r455" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r28", "r44", "r262", "r399", "r424", "r439", "r451" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and shareholders' equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r17", "r58", "r74", "r114", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r207", "r210", "r211", "r225", "r399", "r443", "r454", "r455" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent", "totalLabel": "TOTAL LONG-TERM LIABILITIES", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r18", "r19", "r20", "r21", "r74", "r114", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r207", "r210", "r211", "r225", "r443", "r454", "r455" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LONG-TERM LIABILITIES -", "terseLabel": "LONG-TERM LIABILITIES" } } }, "auth_ref": [] }, "slgl_LicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "LicenseAgreementsAbstract", "lang": { "en-us": { "role": { "label": "License Agreements [Abstract]" } } }, "auth_ref": [] }, "slgl_LicenseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "LicenseAgreementsTextBlock", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreements" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for license agreements information.", "label": "License Agreements Text Block", "verboseLabel": "AGREEMENTS" } } }, "auth_ref": [] }, "slgl_LicenseAgreementsWithBeimeiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "LicenseAgreementsWithBeimeiMember", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "License Agreements With Beimei [Member]", "documentation": "This member stands for License Agreements with Beimei." } } }, "auth_ref": [] }, "slgl_LicenseAgreementsWithGaldermaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "LicenseAgreementsWithGaldermaMember", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License Agreements With Galderma", "label": "License Agreements With Galderma [Member]" } } }, "auth_ref": [] }, "slgl_LicenseAgreementsWithSearchlightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "LicenseAgreementsWithSearchlightMember", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for License Agreements with Searchlight.", "label": "License Agreements With Searchlight [Member]" } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": [ "http://www.sol-gel.co/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "label": "License [Member]", "terseLabel": "Sale of IP and license revenue [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r447" ] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Level 2 securities:" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets", "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails", "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of the period", "periodStartLabel": "Balance at beginning of the period", "label": "Marketable securities", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r418" ] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Marketable Securities", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails", "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r123", "r124", "r125", "r126", "r164", "r193", "r222", "r251", "r275", "r276", "r282", "r297", "r298", "r355", "r357", "r359", "r360", "r364", "r373", "r374", "r385", "r386", "r391", "r395", "r396", "r397", "r398", "r401", "r445", "r456", "r457", "r458", "r459", "r460", "r461" ] }, "slgl_MilestonePaymentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "MilestonePaymentsAxis", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Milestone Payments Axis", "label": "Milestone Payments [Axis]" } } }, "auth_ref": [] }, "slgl_MilestonePaymentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "MilestonePaymentsDomain", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Milestone Payments domain", "label": "Milestone Payments [Domain]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails", "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r123", "r124", "r125", "r126", "r164", "r193", "r222", "r251", "r275", "r276", "r282", "r297", "r298", "r355", "r357", "r359", "r360", "r364", "r373", "r374", "r385", "r386", "r391", "r395", "r396", "r397", "r401", "r445", "r456", "r457", "r458", "r459", "r460", "r461" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperations" ], "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r51", "r52" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r70" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r70" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r33", "r34", "r35" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "slgl_NetChangesInOperatingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "NetChangesInOperatingLeases", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 100.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Net changes in operating leases.", "negatedLabel": "Net changes in operating leases", "label": "Net Changes In Operating Leases" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "NET INCOME (LOSS) FOR THE PERIOD", "label": "Loss", "terseLabel": "Loss for the period", "totalLabel": "NET INCOME (LOSS) FOR THE PERIOD", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r29", "r35", "r45", "r56", "r62", "r63", "r66", "r74", "r78", "r80", "r81", "r82", "r83", "r84", "r87", "r88", "r92", "r114", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r200", "r203", "r221", "r225", "r265", "r327", "r345", "r346", "r413", "r443" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Newly issued and recently adopted accounting pronouncements:", "terseLabel": "Recently issued accounting pronouncements, not yet adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "slgl_NumberOfApprovedGenericDrugProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "NumberOfApprovedGenericDrugProducts", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of approved generic drug products.", "label": "Number Of Approved Generic Drug Products", "terseLabel": "Number of approved generic drug products" } } }, "auth_ref": [] }, "slgl_NumberOfEqualQuarterlyInstalments": { "xbrltype": "integerItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "NumberOfEqualQuarterlyInstalments", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of equal quarterly instalments.", "label": "Number Of Equal Quarterly Instalments", "terseLabel": "Number of equal quarterly instalments" } } }, "auth_ref": [] }, "slgl_NumberOfGenericCollaborativeAgreementsToSellRights": { "xbrltype": "integerItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "NumberOfGenericCollaborativeAgreementsToSellRights", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of generic collaborative agreements to sell the rights.", "label": "Number Of Generic Collaborative Agreements To Sell Rights", "terseLabel": "Number of generic collaborative agreements to sell rights" } } }, "auth_ref": [] }, "slgl_NumberOfGenericDrugCandidates": { "xbrltype": "integerItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "NumberOfGenericDrugCandidates", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of generic drug candidates.", "label": "Number Of Generic Drug Candidates", "terseLabel": "Number of generic drug candidates" } } }, "auth_ref": [] }, "slgl_NumberOfGenericProgramsRetainedForCollaborationRights": { "xbrltype": "integerItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "NumberOfGenericProgramsRetainedForCollaborationRights", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of generic programs retained for collaboration rights.", "label": "Number Of Generic Programs Retained For Collaboration Rights", "terseLabel": "Number of generic programs retained for collaboration rights" } } }, "auth_ref": [] }, "slgl_NumberOfUnapprovedGenericPrograms": { "xbrltype": "integerItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "NumberOfUnapprovedGenericPrograms", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of unapproved generic programs.", "label": "Number Of Unapproved Generic Programs", "terseLabel": "Number of unapproved generic programs" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "OPERATING INCOME (LOSS)", "label": "Operating Income (Loss)", "totalLabel": "OPERATING INCOME (LOSS)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r49", "r382", "r429", "r430", "r431", "r432", "r433" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current maturities of operating leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r236" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating leases liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r236" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r235" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other accounts payable", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r16" ] }, "slgl_OtherForeignGovernmentBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "OtherForeignGovernmentBondsMember", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Other foreign government bonds [Member]", "label": "Other foreign government bonds [Member]" } } }, "auth_ref": [] }, "slgl_OutstandingPrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "OutstandingPrincipalAmount", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of outstanding principal amount.", "label": "Outstanding Principal Amount", "terseLabel": "Outstanding principal amount" } } }, "auth_ref": [] }, "slgl_PaidUpfrontAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "PaidUpfrontAmount", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent amount of upfront payment done.", "label": "Paid Upfront Amount", "terseLabel": "Upfront payment paid" } } }, "auth_ref": [] }, "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PartnerTypeOfPartnersCapitalAccountAxis", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Partner Type [Axis]", "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests." } } }, "auth_ref": [ "r40", "r290" ] }, "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Partner Type of Partners' Capital Account, Name [Domain]", "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests." } } }, "auth_ref": [ "r40", "r290" ] }, "slgl_PaymentReceivableInInstalments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "PaymentReceivableInInstalments", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the value of payment receivable in instalments.", "label": "Payment Receivable In Instalments", "terseLabel": "Payment receivable in instalments" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in marketable securities", "label": "Additions", "terseLabel": "Additions", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r436" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r32" ] }, "slgl_PellepharmMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "PellepharmMember", "presentation": [ "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "The member stands for Pellepharm.", "label": "Pellepharm [Member]", "terseLabel": "PellePharm, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest received", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from issuance of shares and warrants through public offering, net of issuance costs", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from issuance of shares and warrants through placement from the controlling shareholder", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r1" ] }, "slgl_ProceedsFromLongTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "ProceedsFromLongTermDeposits", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of proceeds from long-term deposits.", "label": "Proceeds From Long Term Deposits", "terseLabel": "Proceeds from long-term deposits", "verboseLabel": "Restricted long-term deposits", "positiveLabel": "Long-term deposits" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Sale or maturity", "label": "Proceeds from sales and maturity of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and Equipment", "verboseLabel": "Proceeds from sale of property and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r31" ] }, "slgl_ProceedsFromShortTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "ProceedsFromShortTermDeposits", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of proceeds from short term deposits.", "label": "Proceeds From Short Term Deposits", "terseLabel": "Proceeds from short-term deposits", "verboseLabel": "Short-term deposits" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceed from exercise of options", "terseLabel": "Proceeds from exercise of options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r6" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails", "http://www.sol-gel.co/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r107", "r252", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r377", "r387", "r400", "r401", "r402", "r403", "r404", "r441", "r442", "r446", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails", "http://www.sol-gel.co/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r107", "r252", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r377", "r387", "r400", "r401", "r402", "r403", "r404", "r441", "r442", "r446", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "LOSS FOR THE PERIOD", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Loss for the period", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r56", "r62", "r63", "r69", "r74", "r78", "r84", "r87", "r88", "r114", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r200", "r203", "r205", "r208", "r209", "r221", "r225", "r255", "r264", "r288", "r327", "r345", "r346", "r393", "r394", "r414", "r421", "r443" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r238", "r257", "r263", "r399" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails", "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "verboseLabel": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r123", "r124", "r125", "r126", "r160", "r164", "r189", "r190", "r191", "r193", "r222", "r249", "r250", "r251", "r275", "r276", "r282", "r297", "r298", "r355", "r357", "r359", "r360", "r364", "r373", "r374", "r385", "r386", "r391", "r395", "r396", "r397", "r398", "r401", "r407", "r440", "r445", "r450", "r457", "r458", "r459", "r460", "r461" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails", "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "auth_ref": [ "r123", "r124", "r125", "r126", "r160", "r164", "r189", "r190", "r191", "r193", "r222", "r249", "r250", "r251", "r275", "r276", "r282", "r297", "r298", "r355", "r357", "r359", "r360", "r364", "r373", "r374", "r385", "r386", "r391", "r395", "r396", "r397", "r398", "r401", "r407", "r440", "r445", "r450", "r457", "r458", "r459", "r460", "r461" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 40.0 } }, "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r399" ] }, "slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount represents recognition ofoperating lease right of use assets and liabilities.", "label": "Recognition Of Operating Lease Right Of Use Assets And Liabilities", "terseLabel": "Recognition of new operating lease ROU and liabilities" } } }, "auth_ref": [] }, "slgl_RegulatoryApprovalMilestonePaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "RegulatoryApprovalMilestonePaymentsReceived", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Regulatory approval milestone payments received.", "label": "Regulatory Approval Milestone Payments Received", "terseLabel": "Regulatory approval milestone payments received" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Consideration for agreement", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r13", "r243" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.sol-gel.co/role/RelatedParties" ], "lang": { "en-us": { "role": { "label": "RELATED PARTIES:", "terseLabel": "RELATED PARTIES", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r240", "r241", "r242", "r244", "r245", "r285", "r286", "r287", "r330", "r331", "r332", "r351", "r353" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES", "label": "RESEARCH AND DEVELOPMENT EXPENSES", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r194", "r375", "r383", "r462" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r417", "r423", "r464", "r466" ] }, "us-gaap_RestrictedCashAndInvestmentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndInvestmentsNoncurrent", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted long-term deposits and cash", "verboseLabel": "Restricted long-term deposits and cash equivalents", "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal." } } }, "auth_ref": [ "r371", "r372" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets", "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r25", "r39", "r261", "r280", "r281", "r284", "r308", "r399" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "terseLabel": "Accumulated deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r55", "r75", "r76", "r77", "r79", "r84", "r86", "r88", "r115", "r116", "r122", "r195", "r196", "r197", "r198", "r199", "r201", "r202", "r203", "r212", "r214", "r215", "r217", "r219", "r233", "r234", "r277", "r279", "r289", "r498" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.sol-gel.co/role/REVENUE" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r53", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157" ] }, "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition, Milestone Method, Revenue Recognized", "terseLabel": "Royalties revenues", "documentation": "The amount of consideration recognized during the period for the milestone or milestones." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r328", "r376", "r379" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations", "http://www.sol-gel.co/role/NatureOfOperationsDetails", "http://www.sol-gel.co/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Total revenue", "verboseLabel": "Sales amount", "positiveLabel": "REVENUE", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r47", "r48", "r67", "r74", "r99", "r102", "r103", "r104", "r106", "r107", "r108", "r109", "r114", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r225", "r255", "r383", "r443" ] }, "slgl_RoyaltiesMaturity": { "xbrltype": "stringItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "RoyaltiesMaturity", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Royalties Maturity.", "label": "Royalties Maturity", "terseLabel": "Royalties maturity" } } }, "auth_ref": [] }, "slgl_RoyaltiesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "RoyaltiesPercentage", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Royalties Percentage", "documentation": "The information about the royalties percentage.", "terseLabel": "Royalties percentage" } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": [ "http://www.sol-gel.co/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "label": "Royalty [Member]", "terseLabel": "Royalties revenue [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r447" ] }, "slgl_SalesMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "SalesMilestonePayments", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails", "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent of amount the sales milestone payments", "label": "Sales Milestone Payments", "verboseLabel": "Sales milestone payments" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails", "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r204" ] }, "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Changes in Fair Value of Marketable Securities", "verboseLabel": "Schedule of Summary of Changes in Fair Value of Marketable Securities", "documentation": "Tabular disclosure of derivative assets at fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails", "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assumptions Used to Estimate Fair Value", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": [ "http://www.sol-gel.co/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "label": "Service [Member]", "terseLabel": "Support services [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r387" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "terseLabel": "Share-based compensation expenses", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Option vesting period", "terseLabel": "Option vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r392" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r190" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r189" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r191" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails", "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Option grants", "terseLabel": "Option grants", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r174" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price", "terseLabel": "Exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r170", "r171" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Value of one ordinary share", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r188" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of options granted", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r185" ] }, "slgl_ShortTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "ShortTermDeposits", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 60.0 } }, "lang": { "en-us": { "role": { "documentation": "Short-term deposits.", "negatedLabel": "short-term deposits", "label": "Short Term Deposits" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES:", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r36", "r72" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r23", "r26", "r27", "r55", "r64", "r65", "r66", "r75", "r76", "r77", "r79", "r84", "r86", "r88", "r100", "r115", "r116", "r122", "r148", "r195", "r196", "r197", "r198", "r199", "r201", "r202", "r203", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r239", "r266", "r277", "r278", "r279", "r289", "r347" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails", "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations", "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails", "http://www.sol-gel.co/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r75", "r76", "r77", "r100", "r234", "r252", "r283", "r291", "r299", "r300", "r301", "r302", "r303", "r304", "r307", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324", "r326", "r328", "r329", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r347", "r408" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails", "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations", "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails", "http://www.sol-gel.co/role/REVENUEDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r75", "r76", "r77", "r100", "r110", "r234", "r252", "r283", "r291", "r299", "r300", "r301", "r302", "r303", "r304", "r307", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324", "r326", "r328", "r329", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r347", "r408" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of options, shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r5", "r22", "r23", "r39", "r175" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r5", "r23", "r26", "r27", "r39" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets", "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance", "periodStartLabel": "Balance", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "TOTAL SHAREHOLDERS' EQUITY", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r23", "r26", "r27", "r37", "r309", "r325", "r348", "r349", "r399", "r415", "r424", "r439", "r451", "r498" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.sol-gel.co/role/ShareCapital" ], "lang": { "en-us": { "role": { "label": "SHARE CAPITAL:", "terseLabel": "SHARE BASED COMPENSATION", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r38", "r73", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r218", "r350", "r352", "r370" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r232", "r247" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r232", "r247" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r232", "r247" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r232", "r247" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r232", "r247" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.sol-gel.co/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENT", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r246", "r248" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTARY INFORMATION:" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r434", "r453" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "slgl_TwyneoAndEpsolayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "TwyneoAndEpsolayMember", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Twyneo and Epsolay.", "label": "Twyneo And Epsolay [Member]" } } }, "auth_ref": [] }, "slgl_TwyneoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "TwyneoMember", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Twyneo", "label": "Twyneo [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails", "http://www.sol-gel.co/role/NatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r204" ] }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": [ "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "U.S government and agency bonds [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r465" ] }, "slgl_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "UpfrontPaymentReceived", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/CollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the value of upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "auth_ref": [] }, "slgl_UpfrontPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sol-gel.co/20240630", "localname": "UpfrontPaymentsReceived", "crdr": "credit", "presentation": [ "http://www.sol-gel.co/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Upfront payments received.", "label": "Upfront Payments Received", "terseLabel": "Upfront payments received" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Options and Warrants [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r405", "r406", "r409", "r410", "r411", "r412" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r90", "r95" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE", "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r89", "r95" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r378": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r381": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r382": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r383": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r384": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r385": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r386": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r388": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r391": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r392": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r394": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r395": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r396": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r397": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r398": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r399": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r403": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r405": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r416": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16" }, "r423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" } } } ZIP 50 0001178913-24-002666-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178913-24-002666-xbrl.zip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
81YW>E@O^55@?JF]CY(9(-]V&\Q J1)Z3FP(= M4,D,+Z4L1"Z]/1XYJ,!M#)0R21FDTZX(P9.1C[)&$? M4:JW(@+]D>R3GD#0X/@Z)6X-NO?ZF'#C"[&(/%APH6@3 %\7N#B]36)I3-QV M'J@NA0*%V.H*H9ITUR43O2N42""N"T3C4?$
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zk2431829_htm.xml IDEA: XBRL DOCUMENT 0001684693 2023-01-01 2023-06-30 0001684693 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001684693 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001684693 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001684693 2023-06-30 0001684693 us-gaap:RetainedEarningsMember 2023-06-30 0001684693 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001684693 us-gaap:CommonStockMember 2023-06-30 0001684693 2022-12-31 0001684693 us-gaap:RetainedEarningsMember 2022-12-31 0001684693 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001684693 us-gaap:CommonStockMember 2022-12-31 0001684693 2023-04-01 2023-06-30 0001684693 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001684693 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001684693 2023-03-31 0001684693 us-gaap:RetainedEarningsMember 2023-03-31 0001684693 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001684693 us-gaap:CommonStockMember 2023-03-31 0001684693 2024-01-01 2024-06-30 0001684693 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001684693 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001684693 2024-06-30 0001684693 us-gaap:RetainedEarningsMember 2024-06-30 0001684693 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001684693 us-gaap:CommonStockMember 2024-06-30 0001684693 2024-03-31 0001684693 us-gaap:RetainedEarningsMember 2024-03-31 0001684693 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001684693 us-gaap:CommonStockMember 2024-03-31 0001684693 2024-04-01 2024-06-30 0001684693 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001684693 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001684693 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001684693 2023-12-31 0001684693 us-gaap:RetainedEarningsMember 2023-12-31 0001684693 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001684693 us-gaap:CommonStockMember 2023-12-31 0001684693 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001684693 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001684693 slgl:PellepharmMember slgl:AssetPurchaseAgreementMember slgl:CommercialMilestonesMember 2023-01-30 2023-01-30 0001684693 slgl:PellepharmMember slgl:AssetPurchaseAgreementMember slgl:DevelopmentAndNdaAcceptanceMilestonesMember 2023-01-30 2023-01-30 0001684693 slgl:PellepharmMember slgl:AssetPurchaseAgreementMember slgl:CommercialMilestonesMember 2024-03-01 2024-03-31 0001684693 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001684693 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001684693 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001684693 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001684693 us-gaap:GeneralPartnerMember us-gaap:SubsequentEventMember 2024-08-15 2024-08-15 0001684693 us-gaap:RoyaltyMember 2023-01-01 2023-06-30 0001684693 us-gaap:RoyaltyMember 2024-01-01 2024-06-30 0001684693 us-gaap:LicenseMember 2024-01-01 2024-06-30 0001684693 us-gaap:LicenseMember 2023-01-01 2023-06-30 0001684693 us-gaap:RoyaltyMember 2023-04-01 2023-06-30 0001684693 us-gaap:LicenseMember 2023-04-01 2023-06-30 0001684693 us-gaap:RoyaltyMember 2024-04-01 2024-06-30 0001684693 us-gaap:LicenseMember 2024-04-01 2024-06-30 0001684693 us-gaap:ServiceMember 2024-04-01 2024-06-30 0001684693 us-gaap:ServiceMember 2023-04-01 2023-06-30 0001684693 us-gaap:ServiceMember 2024-01-01 2024-06-30 0001684693 us-gaap:ServiceMember 2023-01-01 2023-06-30 0001684693 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001684693 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-06-30 0001684693 slgl:OtherForeignGovernmentBondsMember 2023-12-31 0001684693 us-gaap:AllOtherCorporateBondsMember 2023-12-31 0001684693 us-gaap:AllOtherCorporateBondsMember 2024-06-30 0001684693 2023-01-01 2023-12-31 0001684693 slgl:OtherForeignGovernmentBondsMember 2024-06-30 0001684693 srt:DirectorMember 2024-01-01 2024-06-30 0001684693 srt:DirectorMember 2024-01-01 2024-01-31 0001684693 srt:DirectorMember 2024-01-31 0001684693 srt:MinimumMember 2007-01-01 2007-12-31 0001684693 srt:MaximumMember 2007-01-01 2007-12-31 0001684693 2021-11-01 0001684693 slgl:TwyneoMember slgl:LicenseAgreementsWithGaldermaMember 2021-06-01 2021-06-30 0001684693 slgl:TwyneoAndEpsolayMember slgl:LicenseAgreementsWithSearchlightMember 2023-06-01 2023-06-06 0001684693 slgl:TwyneoAndEpsolayMember slgl:LicenseAgreementsWithGaldermaMember 2024-01-01 2024-06-30 0001684693 slgl:TwyneoAndEpsolayMember slgl:LicenseAgreementsWithGaldermaMember 2021-06-01 2021-06-30 0001684693 slgl:TwyneoAndEpsolayMember slgl:LicenseAgreementsWithSearchlightMember 2023-01-01 2023-06-30 0001684693 slgl:TwyneoAndEpsolayMember slgl:LicenseAgreementsWithSearchlightMember 2024-01-01 2024-06-30 0001684693 slgl:TwyneoAndEpsolayMember slgl:LicenseAgreementsWithGaldermaMember 2023-01-01 2023-06-30 0001684693 slgl:TwyneoMember slgl:LicenseAgreementsWithBeimeiMember 2024-01-01 2024-06-30 slgl:Agreement slgl:Candidate iso4217:ILS shares slgl:Program shares iso4217:USD shares pure iso4217:USD 0001684693 --12-31 false 6-K 2024-06-30 Q2 6-K 2024 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir Street Ness Ziona 7403650 IL 7513000 11549000 10012000 4012000 20471000 14912000 377000 6059000 2794000 1750000 41167000 38282000 1284000 1273000 434000 305000 1721000 1507000 55000 34000 626000 604000 4120000 3723000 45287000 42005000 154000 679000 3921000 4147000 447000 376000 4522000 5202000 1206000 1018000 915000 883000 2121000 1901000 6643000 7103000 0.1 0.1 50000000 50000000 27857620 27857620 27857620 27857620 774000 774000 258173000 258799000 -220303000 -224671000 38644000 34902000 45287000 42005000 894000 5899000 594000 5433000 14698000 7783000 5312000 2438000 3786000 3203000 1809000 1371000 -17590000 -5087000 -6527000 1624000 899000 719000 557000 352000 -16691000 -4368000 -5970000 1976000 -0.63 -0.63 -0.16 -0.16 -0.22 -0.22 0.07 0.07 26306484 26306484 27857620 27857620 27660326 27660326 27857620 27857620 23129469 638000 234640000 -193065000 42213000 -16691000 -16691000 2560000 74000 11468000 11542000 2000000 56000 9944000 10000000 116485 3000 177000 180000 1052000 1052000 27805954 771000 257281000 -209756000 48296000 27857620 774000 258173000 -220303000 38644000 0 0 -4368000 -4368000 0 0 626000 626000 27857620 774000 258799000 -224671000 34902000 25702237 712000 246678000 -203786000 43604000 -5970000 -5970000 2000000 56000 9944000 10000000 103717 3000 161000 164000 498000 498000 27805954 771000 257281000 -209756000 48296000 27857620 774000 258524000 -226647000 32651000 0 0 1976000 1976000 0 0 275000 275000 27857620 774000 258799000 -224671000 34902000 -16691000 -4368000 185000 125000 -9000 10000 1052000 626000 -1000 -2000 36000 45000 66000 87000 -5653000 0 0 5682000 1063000 -1065000 2623000 751000 -8335000 -7627000 94000 0 0 4000 17114000 0 7995000 5646000 -1000000 6000000 12000 821000 -10201000 12471000 180000 0 10000000 0 11542000 0 21722000 0 1000 2000 3187000 4846000 13598000 7863000 16785000 12709000 15618000 11549000 1167000 1160000 16785000 12709000 190000 0 590000 1121000 <div> <div> <div> <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1 - NATURE OF OPERATIONS</span></span><br/> </div> <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sol-Gel Technologies Ltd. (collectively with its U.S. subsidiary, the Company) is an Israeli Company incorporated in 1997.</span></span><br/> </div> <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is an innovative dermatology company with a successful track record of two NDA approvals and advanced orphan drugs pipeline. The Company has two approved drugs: (i) Twyneo®, which was developed for the treatment of acne vulgaris and received marketing authorization by the U.S. Food and Durg Administration (the "FDA") on July 27, 2021 and (ii) Epsolay®, a treatment for subtype II rosacea that received marketing authorization by the FDA on April 25, 2022. In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of Twyneo® and Epsolay® in the United States, see Note 6a. On April 14, 2022, the Company announced that Twyneo® is available for purchase by consumers who obtain a prescription from their physician. On June 2, 2022, the Company announced that Epsolay® is available for purchase by consumers who obtain a prescription from their physician. In addition to the novel products, the Company’s products included the approved generic products Acyclovir, Ivermectin and other generic product candidates. In November 2021, the Company entered into an agreement with Padagis, to sell its rights in relation to ten generic collaborative agreements between the parties, including the agreements for the two aforementioned approved generic drug products. Under the new agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, see note 5c.</span></span><br/> </div> <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 27, 2023 the Company entered into an asset purchase agreement ("APA") with PellePharm, Inc. (hereafter-“PellePharm”), pursuant to which the Company agreed to purchase all of the assets related to the topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome (such compound designated as investigational compound SGT-610). On January 30, 2023, upon closing of the transaction, the Company paid an upfront payment (hereafter- "upfront payment") of $4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date. In addition, the Company will be required to pay total development and NDA acceptance milestones of up to $6 million, and up to $64 million in commercial milestones which amount increases to $89 million when sales exceed $500 million as well as single digit royalties which increase to double digit royalties when sales exceed $500 million. During March 2024 the first developement milestone event has completed and the Company recorded an amount of $500 as clinical expenses.</span></span><br/> </div> <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The upfront payment and the additional development milestone payments under the APA represent payments for research and development in-process ("IPR&D") acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use. Accordingly, such payments were expensed as incurred and recognized as research and development expenses.</span></span><br/> </div> <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 15, 2024, the Company and Shenzhen Beimei Pharmaceutical Co. Ltd. ("Beimei"), entered into an asset purchase agreement, For further details, see Note 6c.</span></span><br/> </div> <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regards to marketing, regulatory affairs and business development relating to its products and technology in the U.S.</span></span><br/> </div> <div style="text-align:justify;margin-left:20pt;line-height:1.25;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, Hamas terrorists infiltrated Israel’s southern border and launched a series of attacks against Israel. Following these attacks, Israel’s security cabinet declared war against Hamas and initiated a military campaign. As of the issuance date of this report, there was no material impact on the Company's ongoing operations in Israel. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employee</span></span></div> <div style="text-align:justify;margin-left:20pt;line-height:1.25;margin-bottom:0pt"> </div> <div></div> <div style="text-align:justify;margin-left:20pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk and Uncertainties</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since incorporation through June 30, 2024, the Company has an accumulated deficit of $224,671 and its activities have been funded mainly by its shareholders, collaboration revenues and license agreements, see also Notes 5 and 6. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of June 30, 2024 will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.</span></span></div> </div> </div> </div> $4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date. 6000000 64000000 89000000 500000000 500000000 500000 -224671000 <div> <div style="text-align:justify;text-indent:-7.1pt;margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:<br/> </span></span></span></div> <div> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td> <td style="width:auto;vertical-align:top;margin-top:0pt;margin-bottom:0pt"> <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">Basis of Presentation</span></span></span></span></span><br/> </div> <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.</span></span></span></span></div> </td> </tr> </table> </div> <div style="margin-left:36pt;line-height:1.25;text-align:justify"> </div> <div style="margin-left:36pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:35.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.</span></span></span></span></div> </div> <div style="line-height:1.25"> </div> <div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Earnings (Loss) per share</span></span></span></span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted earnings per share, does not include 6,501,769 options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted loss per share does not include 6,993,858 options and warrants for the six months ended June 30, 2024 and 5,961,999 and 7,120,463 options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.</span></span></span></span></div> </div> <p style="margin:0pt"> </p> <div style="line-height:1.25;font-weight:400;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"> <div></div> </div> <div style="line-height:1.25;font-weight:400;font-family:'Times New Roman',Times,serif"> <div> <div> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top"> <div> <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently issued accounting pronouncements, not yet adopted</span></span></div> <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.</span></span></div> </div> </td> </tr> </table> </div> </div> </div> </div> </div> <div> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td> <td style="width:auto;vertical-align:top;margin-top:0pt;margin-bottom:0pt"> <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">Basis of Presentation</span></span></span></span></span><br/> </div> <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.</span></span></span></span></div> </td> </tr> </table> </div> <div style="margin-left:36pt;line-height:1.25;text-align:justify"> </div> <div style="margin-left:36pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:35.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.</span></span></span></span></div> </div> <div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Earnings (Loss) per share</span></span></span></span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted earnings per share, does not include 6,501,769 options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted loss per share does not include 6,993,858 options and warrants for the six months ended June 30, 2024 and 5,961,999 and 7,120,463 options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.</span></span></span></span></div> </div> 6501769 6993858 5961999 7120463 <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top"> <div> <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently issued accounting pronouncements, not yet adopted</span></span></div> <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.</span></span></div> </div> </td> </tr> </table> <div> <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3 - MARKETABLE SECURITIES:</span></span></div> <div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the Company’s marketable securities for the indicated periods:</span></span></div> <div style="margin-left:36pt;line-height:1.25"> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:bottom;padding-left:9pt;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 securities:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S government and agency bonds</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,583</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,612</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other foreign government bonds</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,946</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,974</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate bonds*</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,942</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,326</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Investments in Corporate bonds rated A or higher.</span></span></div> </div> <div style="margin-left:36pt;line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-right:35.45pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the indicated periods:</span></span></div> <div style="margin-right:35.45pt;margin-left:36pt;line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketable securities</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the year ended</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ended June 30, 2024</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at beginning of the period</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,678</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,164</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale or maturity</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,807</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,646</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value during the period</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">436</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at end of the period</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> <p style="margin:0pt"> </p> </div> </div> <div></div> <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024, the Company’s debt securities had the following maturity dates:</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market value</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;padding-left:9pt;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;text-indent:-2.5pt;margin-right:7.1pt;margin-left:20.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due within one year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of bank deposits approximates their carrying value, since they bear interest at rates close to the prevailing market rates. In addition, due to the short-term nature and/or low-risk nature of the Company's cash and cash equivalents, restricted cash equivalents, accounts receivable, accounts payable and other payables , their carrying amounts approximates their fair value</span></span></div> </div> </div> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:bottom;padding-left:9pt;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 securities:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S government and agency bonds</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,583</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,612</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other foreign government bonds</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,946</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,974</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate bonds*</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,942</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,326</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Investments in Corporate bonds rated A or higher.</span></span></div> </div> 2583000 1612000 1946000 1974000 15942000 11326000 20471000 14912000 <div> <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketable securities</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the year ended</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ended June 30, 2024</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at beginning of the period</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,678</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,164</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale or maturity</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,807</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,646</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value during the period</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">436</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at end of the period</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> <p style="margin:0pt"> </p> </div> 8678000 20471000 23164000 0 11807000 5646000 -436000 87000 20471000 14912000 <div> <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market value</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;padding-left:9pt;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;text-indent:-2.5pt;margin-right:7.1pt;margin-left:20.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due within one year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> 14912000 <div> <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4 - REVENUE:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-right:35.45pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the Company’s revenues for the indicated periods:</span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span> </span></span></span></div> <div style="line-height:1.25;margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three months ended</span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties revenue</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">514</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,056</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">214</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">612</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of IP and license revenue</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">380</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,800</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">380</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,800</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Support services</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">21</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenue</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">894</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,899</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">594</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,433</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three months ended</span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties revenue</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">514</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,056</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">214</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">612</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of IP and license revenue</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">380</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,800</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">380</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,800</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Support services</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">21</span></span></div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenue</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">894</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,899</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">594</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,433</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 514000 1056000 214000 612000 380000 4800000 380000 4800000 0 43000 0 21000 894000 5899000 594000 5433000 <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 5 - COLLABORATION AGREEMENTS:<br/> </span></span></p> <div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:20pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif">a.</span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-family:Times New Roman,Times,serif">In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales, royalties are not material.</span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:20pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif">b.</span></td> <td style="width:auto;vertical-align:top"> <div style="text-align:justify"><span style="font-family:Times New Roman,Times,serif">In 2016 through 2020, the Company entered into several collaboration agreements mainly with one third party (the "Partner") for the development, manufacturing and commercialization of several product candidates (including an agreement assumed by the Company in August 2018, following the transfer of an in-process research and development product candidate from a related party).</span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:20pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif">c.</span></td> <td style="width:auto;vertical-align:top"> <div style="text-align:justify"><span style="font-family:Times New Roman,Times,serif">Under the agreements, the Partner is obligated to conduct regulatory, scientific, clinical and technical activities necessary to develop the products and prepare and file an abbreviated new drug application ("ANDA"), with the FDA and gain regulatory approval. The Company participates in the development of the product candidates, including participation in joint steering committees and is obligated for sourcing the active pharmaceutical ingredient (API) during the development phase.</span></div> <div> </div> <div style="text-align:justify"><span style="font-family:Times New Roman,Times,serif">Upon FDA approval, the Partner has exclusive rights and is required to use diligent efforts to commercialize these products in territories defined under the agreements, including all required sales, marketing and distributing activities associated with the agreements. The Company is entitled to a share of the Partner's gross profits related to the sale of the products, as such term is defined in each of the agreements.</span></div> <div> </div> </td> </tr> </table> <div></div> <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These Agreements are considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company recognizes collaboration revenues when the related sales occur.</span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In November 2021, the Company entered into a new agreement ("New Agreement") with the Partner, to sell its rights to the Partner in relation to ten generic collaborative agreements between the parties in consideration of $21,500 which was paid over 24 months. Under the New Agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, and is no longer entitled to receive its share in profit as detailed above.</span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In addition, the Company ceased paying any outstanding and future operational costs related to these collaborative agreements.</span></span></span></div> <div style="text-align:justify;margin-left:38pt;line-height:1.25"> </div> <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In August 15, 2024 the Company entered into a Termination Agreement with the Partner, For further details, see note 9.</span></span></span></div> </div> </div> 2016 2024 10 21500000 2 4 <div> <div style="margin-left:0px"> <div> <div> <div style="text-align:justify;line-height:1.25;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE</span> <span style="font-weight:bold">6 - AGREEMENTS:</span></span></span></div> <div> <div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td> <td style="vertical-align:top;text-align:justify;width:auto"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of two of the Company's most advanced investigational drug products (Twyneo® and Epsolay®) in the United States. The Company was entitled to amounts of up to $7.5 million per product in upfront payments and regulatory approval milestone payments assuming 2021 approval of each respective product. The Company is also eligible to receive tiered double-digit royalties ranging from mid-teen to high-teen percentage of net sales as well as up to $9 million in sales milestone payments.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">According to the agreement, the Company has an option to regain commercialization rights five years following first commercialization.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 14, 2022, the Company announced that Twyneo® is available for purchase by consumers who obtain a prescription from their physician, See note 1. On June 2, 2022, the Company announced that Epsolay® is available for purchase by consumers who obtain a prescription from their physician, See also note 1.<span style="font-weight:bold"> </span>The Company recognized $723 and $466 during the six-month periods ended June 30, 2024 and 2023, respectively, as royalty revenue in respect of the license agreement for both products.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 6, 2023, the Company and Searchlight Pharma Inc. (“Searchlight”), a private Canadian specialty pharmaceutical company, signed on an exclusive license agreements for Twyneo® and Epsolay® for the Canadian market, over a fifteen-year term that is renewable for subsequent five-year periods. Searchlight will be responsible for obtaining and maintaining any regulatory approvals required to market and sell the drugs in Canada, with support from the Company.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the agreement, the Company will receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined. In addition, the Company will be entitled to royalty percentages of all Canadian net sales ranging from low-double-digits to high teens.</span></span></div> <div style="text-align:justify;line-height:1.25;margin-left:54pt"> </div> <div></div> <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2023, the Company received $500 as an upfront payment in connection with the license agreement and related support provided to Searchlight for obtaining the regulatory approval in the Canadian market. The Company is also required to support Searchlight during such period if needed based on agreed upon rates. The Company has identified two performance obligations in the license agreement as follows: (i) the license to market the products in Canada; and (ii) continuing support during the regulatory approval process.</span></span></div> <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"> </div> <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six-month period ended June 30, 2024, the Company recognized a total amount of $42 for continuing support. The remaining outstanding contract liability in respect of the support services, is, as of June 30, 2024 $78 .</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 15, 2024, the Company and Beimei, a private Chinese company, signed an agreement for the purchase and license by Beimei of certain rights in the intellectual property ("IP") related to Twyneo, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.</span></span></div> </td> </tr> </table> <div> <div> <div style="line-height:1.25"> </div> <div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the agreement, Beimei will purchase and license from the Company the IP in these territories. The Company is also required to support Beimei to a certain extent during the period until obtaining regulatory approval. The Company may provide further support services to Beimei, if needed, based on agreed upon rates. In return, Sol-Gel is to receive payments of up to $10 million (including amounts contingent on achieving certain milestones) and up to $5 million as royalty payments on net sales.</span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span> </span></span></span></div> </div> <div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has identified multiple performance obligations in the agreement. Revenue from sale and license of IP is recognized at a point in time, upon transfer of control over the license and the IP to Beimei. Support services are recognized over time as the services are performed.</span></span></div> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six-month period ended June 30, 2024, the Company recognized revenue for a total amount of $4.8 million. This amount does not include variable consideration that was determined to be constrained (not probable that would not result in a significant reversal). In addition, the Company recorded $200 as a contract liability in respect of the support services.</span></span></div> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In July 2024, the Company received $2 million as the first payment in connection with the agreement.</span></span></div> </div> </div> </div> </div> </div> </div> </div> </div> 7500000 9000000 723000 466000 11000000 500000 42000 78000 10000000 5000000 4800000 200000 2000000 <div> <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE</span> <span style="font-weight:bold">7 - SHARE BASED COMPENSATION:</span></span></span></p> <div> <div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six months ended June 30, 2024, the Company granted 300,000 options to Directors as follows:</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2024, the board of directors approved and recommended the Company's shareholders to approve a grant of 300,000 options to the Company's Directors to purchase ordinary shares at an exercise price of $1.2 per share. The Company's shareholders approved the grant in February 28, 2024.</span></span></div> <div style="margin-left:35.45pt;line-height:1.25"> </div> <div style="margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The options vest over a period of 3 years; one third of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over the following two years. The options expire on the tenth anniversary of their grant date.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of options granted in 2024 was $207. The underlying data used for computing the fair value of the options are as follows:</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value of one ordinary share</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.2</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">72</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.8</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;text-indent:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4 years</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> </div> </div> </div> 300000 300000 1.2 P3Y 207000 <div> <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value of one ordinary share</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.2</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">72</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.8</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;text-indent:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4 years</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> 1.2 0 0.72 0.048 P4Y <div> <div> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 8 - RELATED PARTIES:<br/> </span></span></span></div> <div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Related parties include the controlling shareholder and companies under his control, the board of directors and the executive officers of the Company.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As to options granted to directors and executive officers, see note 7.</span></span></div> </td> </tr> </table> </div> </div> </div> </div> <div> <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 9 <span style="font-weight:bold">–</span> SUBSEQUENT EVENT</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:38pt;line-height:1.25;font-family:'Palatino Linotype', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">In August 15, 2024, the Company entered into a </span><span>Termination Agreement </span><span style="color:rgb(0, 0, 0)">("the Agreement") with the Partner. The purpose of the Agreement is to terminate the Development, Manufacturing and Commercialization Agreement dated June 28, 2020, and to sell its rights to the Partner in relation to Roflumilast cream and Roflumilast foam. As </span><span>consideration </span><span style="color:rgb(0, 0, 0)">for the Agreement between the parties, the Partner will pay to the Company $4,250, which will paid </span><span>in quarterly installments </span><span style="color:rgb(0, 0, 0)">during 24 months. In addition, in the end of each quarter for five years as of the Launch Date (the date of first commercial sale of the Product in the Territory by the Partner or its Affiliates pursuant to the ANDA), the Partner shall pay Sol-Gel 2% royalties of the Partner’s Gross Profits for that Product.</span></span></span></div> </div> 4250000 0.02

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2024
Cover [Abstract]
Entity Central Index Key	0001684693
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false
Document Type	6-K
Document Period End Date	Jun. 30, 2024
Entity Registrant Name	SOL-GEL TECHNOLOGIES LTD.
Entity Address, Address Line One	7 Golda Meir Street
Entity Address, City or Town	Ness Ziona
Entity Address, Postal Zip Code	7403650
Entity Address, Country	IL

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 11,549	$ 7,513
Bank deposits	4,012	10,012
Marketable securities	14,912	20,471
Accounts receivables	6,059	377
Prepaid expenses and other current assets	1,750	2,794
TOTAL CURRENT ASSETS	38,282	41,167
NON-CURRENT ASSETS:
Restricted long-term deposits and cash equivalents	1,273	1,284
Property and equipment, net	305	434
Operating lease right-of-use assets	1,507	1,721
Other long-term assets	34	55
Funds in respect of employee rights upon retirement	604	626
TOTAL NON-CURRENT ASSETS	3,723	4,120
TOTAL ASSETS	42,005	45,287
CURRENT LIABILITIES:
Accounts payable	679	154
Other accounts payable	4,147	3,921
Current maturities of operating leases	376	447
TOTAL CURRENT LIABILITIES	5,202	4,522
LONG-TERM LIABILITIES
Operating leases liabilities	1,018	1,206
Liability for employee rights upon retirement	883	915
TOTAL LONG-TERM LIABILITIES	1,901	2,121
TOTAL LIABILITIES	7,103	6,643
SHAREHOLDERS' EQUITY:
Ordinary Shares, NIS 0.1 par value – authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of December 31, 2023 and June 30, 2024.	774	774
Additional paid-in capital	258,799	258,173
Accumulated deficit	(224,671)	(220,303)
TOTAL SHAREHOLDERS' EQUITY	34,902	38,644
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 42,005	$ 45,287

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - ₪ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Ordinary shares, par value	₪ 0.1	₪ 0.1
Ordinary shares, shares authorized	50,000,000	50,000,000
Ordinary shares, shares issued	27,857,620	27,857,620
Ordinary shares, shares outstanding	27,857,620	27,857,620

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
REVENUE	$ 5,433	$ 594	$ 5,899	$ 894
RESEARCH AND DEVELOPMENT EXPENSES	2,438	5,312	7,783	14,698
GENERAL AND ADMINISTRATIVE EXPENSES	1,371	1,809	3,203	3,786
OPERATING INCOME (LOSS)	1,624	(6,527)	(5,087)	(17,590)
FINANCIAL INCOME, net	352	557	719	899
NET INCOME (LOSS) FOR THE PERIOD	$ 1,976	$ (5,970)	$ (4,368)	$ (16,691)
BASIC EARNINGS (LOSS) PER ORDINARY SHARE	$ 0.07	$ (0.22)	$ (0.16)	$ (0.63)
DILUTED EARNINGS (LOSS) PER ORDINARY SHARE	$ 0.07	$ (0.22)	$ (0.16)	$ (0.63)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE	27,857,620	27,660,326	27,857,620	26,306,484
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE	27,857,620	27,660,326	27,857,620	26,306,484

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Ordinary shares [Member]	Additional Paid-In Capital [Member]	Accumulated deficit [Member]	Total
Balance at Dec. 31, 2022	$ 638	$ 234,640	$ (193,065)	$ 42,213
Balance, shares at Dec. 31, 2022	23,129,469
Loss for the period			(16,691)	(16,691)
Issuance of shares and warrants through public offering, net of issuance costs	$ 74	11,468		11,542
Issuance of shares and warrants through public offering, net of issuance costs Shares	2,560,000
Issuance of shares and warrants through private placement from the controlling shareholder	$ 56	9,944		10,000
Issuance of shares and warrants through private placement from the controlling shareholder Shares	2,000,000
Exercise of options	$ 3	177		180
Exercise of options, shares	116,485
Share-based compensation		1,052		1,052
Balance at Jun. 30, 2023	$ 771	257,281	(209,756)	48,296
Balance, shares at Jun. 30, 2023	27,805,954
Balance at Mar. 31, 2023	$ 712	246,678	(203,786)	43,604
Balance, shares at Mar. 31, 2023	25,702,237
Loss for the period			(5,970)	(5,970)
Issuance of shares and warrants through private placement from the controlling shareholder	$ 56	9,944		10,000
Issuance of shares and warrants through private placement from the controlling shareholder Shares	2,000,000
Exercise of options	$ 3	161		164
Exercise of options, shares	103,717
Share-based compensation		498		498
Balance at Jun. 30, 2023	$ 771	257,281	(209,756)	48,296
Balance, shares at Jun. 30, 2023	27,805,954
Balance at Dec. 31, 2023	$ 774	258,173	(220,303)	$ 38,644
Balance, shares at Dec. 31, 2023	27,857,620			27,857,620
Loss for the period	$ 0		(4,368)	$ (4,368)
Share-based compensation	0	626		626
Balance at Jun. 30, 2024	$ 774	258,799	(224,671)	$ 34,902
Balance, shares at Jun. 30, 2024	27,857,620			27,857,620
Balance at Mar. 31, 2024	$ 774	258,524	(226,647)	$ 32,651
Balance, shares at Mar. 31, 2024	27,857,620
Loss for the period	$ 0		1,976	1,976
Share-based compensation	0	275		275
Balance at Jun. 30, 2024	$ 774	$ 258,799	$ (224,671)	$ 34,902
Balance, shares at Jun. 30, 2024	27,857,620			27,857,620

NATURE OF OPERATIONS	6 Months Ended
NATURE OF OPERATIONS	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1 - NATURE OF OPERATIONS Sol-Gel Technologies Ltd. (collectively with its U.S. subsidiary, the Company) is an Israeli Company incorporated in 1997. The Company is an innovative dermatology company with a successful track record of two NDA approvals and advanced orphan drugs pipeline. The Company has two approved drugs: (i) Twyneo®, which was developed for the treatment of acne vulgaris and received marketing authorization by the U.S. Food and Durg Administration (the "FDA") on July 27, 2021 and (ii) Epsolay®, a treatment for subtype II rosacea that received marketing authorization by the FDA on April 25, 2022. In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of Twyneo® and Epsolay® in the United States, see Note 6a. On April 14, 2022, the Company announced that Twyneo® is available for purchase by consumers who obtain a prescription from their physician. On June 2, 2022, the Company announced that Epsolay® is available for purchase by consumers who obtain a prescription from their physician. In addition to the novel products, the Company’s products included the approved generic products Acyclovir, Ivermectin and other generic product candidates. In November 2021, the Company entered into an agreement with Padagis, to sell its rights in relation to ten generic collaborative agreements between the parties, including the agreements for the two aforementioned approved generic drug products. Under the new agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, see note 5c. On January 27, 2023 the Company entered into an asset purchase agreement ("APA") with PellePharm, Inc. (hereafter-“PellePharm”), pursuant to which the Company agreed to purchase all of the assets related to the topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome (such compound designated as investigational compound SGT-610). On January 30, 2023, upon closing of the transaction, the Company paid an upfront payment (hereafter- "upfront payment") of $4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date. In addition, the Company will be required to pay total development and NDA acceptance milestones of up to $6 million, and up to $64 million in commercial milestones which amount increases to $89 million when sales exceed $500 million as well as single digit royalties which increase to double digit royalties when sales exceed $500 million. During March 2024 the first developement milestone event has completed and the Company recorded an amount of $500 as clinical expenses. The upfront payment and the additional development milestone payments under the APA represent payments for research and development in-process ("IPR&D") acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use. Accordingly, such payments were expensed as incurred and recognized as research and development expenses. On May 15, 2024, the Company and Shenzhen Beimei Pharmaceutical Co. Ltd. ("Beimei"), entered into an asset purchase agreement, For further details, see Note 6c. The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regards to marketing, regulatory affairs and business development relating to its products and technology in the U.S. In October 2023, Hamas terrorists infiltrated Israel’s southern border and launched a series of attacks against Israel. Following these attacks, Israel’s security cabinet declared war against Hamas and initiated a military campaign. As of the issuance date of this report, there was no material impact on the Company's ongoing operations in Israel. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employee Risk and Uncertainties Since incorporation through June 30, 2024, the Company has an accumulated deficit of $224,671 and its activities have been funded mainly by its shareholders, collaboration revenues and license agreements, see also Notes 5 and 6. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations. Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of June 30, 2024 will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.

SUBSEQUENT EVENT	6 Months Ended
SUBSEQUENT EVENT	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 9 – SUBSEQUENT EVENT In August 15, 2024, the Company entered into a Termination Agreement ("the Agreement") with the Partner. The purpose of the Agreement is to terminate the Development, Manufacturing and Commercialization Agreement dated June 28, 2020, and to sell its rights to the Partner in relation to Roflumilast cream and Roflumilast foam. As consideration for the Agreement between the parties, the Partner will pay to the Company $4,250, which will paid in quarterly installments during 24 months. In addition, in the end of each quarter for five years as of the Launch Date (the date of first commercial sale of the Product in the Territory by the Partner or its Affiliates pursuant to the ANDA), the Partner shall pay Sol-Gel 2% royalties of the Partner’s Gross Profits for that Product.

NATURE OF OPERATIONS (Narrative) (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 30, 2023	Mar. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accumulated deficit			$ (224,671)		$ (224,671)		$ (220,303)
Sales amount			$ 5,433	$ 594	$ 5,899	$ 894
PellePharm, Inc. [Member] \| Asset Purchase Agreement [Member] \| Development And Nda Acceptance Milestones [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone payments	$ 6,000
PellePharm, Inc. [Member] \| Asset Purchase Agreement [Member] \| Commercial Milestones [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone payments	$ 64,000
Description of upfront payment	$4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date.
Increase in sales milestone amount due to sales exceed dollar 500 million	$ 89,000
Sales amount	$ 500,000
Clinical expenses		$ 500

MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due within one year	$ 14,912

REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
REVENUE (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Total revenue	$ 5,433	$ 594	$ 5,899	$ 894
Royalties revenue [Member]
Total revenue	612	214	1,056	514
Sale of IP and license revenue [Member]
Total revenue	4,800	380	4,800	380
Support services [Member]
Total revenue	$ 21	$ 0	$ 43	$ 0

COLLABORATION AGREEMENTS (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2007	Nov. 01, 2021 USD ($) Agreement Candidate Program
Number of generic collaborative agreements to sell rights \| Agreement		10
Number of generic programs retained for collaboration rights \| Program		2
Number of generic drug candidates \| Candidate		4
Expected revenue receivable over twenty four months \| $		$ 21,500
Minimum [Member]
Royalties maturity	2016
Maximum [Member]
Royalties maturity	2024

AGREEMENTS (Narrative) (Details) - USD ($) $ in Thousands		1 Months Ended	6 Months Ended
AGREEMENTS (Narrative) (Details) - USD ($) $ in Thousands	Jun. 06, 2023	Jun. 30, 2021	Jun. 30, 2024	Jun. 30, 2023
Twyneo [Member] \| License Agreements With Galderma [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Regulatory approval milestone payments received		$ 7,500
Twyneo [Member] \| License Agreements With Beimei [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone payments			$ 2,000
Upfront payments received			10,000
Royalties revenues			5,000
Contract liability			200
Estimated variable consideration			4,800
Twyneo And Epsolay [Member] \| License Agreements With Galderma [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone payments		$ 9,000
Royalties revenues			723	$ 466
Twyneo And Epsolay [Member] \| License Agreements With Searchlight [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments received	$ 11,000			$ 500
Royalties revenues			42
Contract liability			$ 78

SHARE BASED COMPENSATION (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Jan. 31, 2024	Jun. 30, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options granted		$ 207
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option grants	300,000	300,000
Exercise price	$ 1.2
Option vesting period	3 years

SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of one ordinary share	$ 1.2
Dividend yield	0.00%
Expected volatility	72.00%
Risk-free interest rate	4.80%
Expected term	4 years

SUBSEQUENT EVENT (Narrative) (Details) - Subsequent Event [Member] - Partner [Member] $ in Thousands	Aug. 15, 2024 USD ($)
Subsequent Event [Line Items]
Consideration for agreement	$ 4,250
Royalties percentage	2.00%